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Abstract 
 
Introduction 
Chronic HIV-1 infection is characterized by extensive inflammation/immune activation and 
also by anaemia. Macrophages and neutrophils produce reactive oxygen species (ROS) 
which can cause damage to surrounding cells, including erythrocytes. Damaged erythrocytes 
may die by apoptosis (erythroptosis) or be tagged for clearance by monocytes/ 
macrophages. In this study we investigated HIV-1-associated anaemia and erythroptosis in 
asymptomatic, untreated HIV-1 infected individuals and how it relates to oxidative stress and 
immune activation.  
Materials and Methods 
This cross-sectional study included 44 chronically HIV-1 infected individuals (CD4 count > 
200) and 33 matched control uninfected individuals. CD4 count, viral load, and haemoglobin 
levels were measured. Red blood cells (RBCs) were stained with annexin V for determining 
ex vivo levels of erythroptosis. Erythrocytes were also subjected to oxidative stress (5mM 
H2O2 or 5mM ascorbic acid), in the presence or absence of N-acetyl cysteine (NAC). Finally, 
RBCs were also stained with CFSE, stimulated with H2O2 and then incubated with purified 
monocytes to monitor monocyte uptake of RBCs. 
Results 
Asymptomatic chronically HIV-1 infected individuals had reduced haemoglobin levels as 
compared to matched controls (12.9g/dL vs. 14.1g/dL, p=0.0172). The reduced haemoglobin 
was mirrored by significantly higher RBC-associated annexin V baseline expression in the 
HIV-1 infected group (13.4% vs. 10.4%, p=0.0189). Annexin V expression increased in both 
groups when stimulated with H2O2. Although NAC inhibited induced oxidative stress in both 
groups, the uninfected group displayed stronger inhibition. The in vitro oxidative stress 
induced percentage of apoptotic RBCs was significantly reduced in the control group 
(20±5.1% to 15±4.4%, p=0.0063), but not the HIV-1 positive group (18.3±5.0% to 16±5.2%, 
(p=0.0649)). There was a significant increase in the percentage inflammatory monocytes in 
the HIV-1 infected group, with the control group median inflammatory monocyte comprising  
5.3±3.8% when compared to the HIV-1 positive group  8.3±3.5%, p=0.0054. In the HIV-1 
infected individuals there was a higher number of inflammatory monocyte phagocytosing 
oxidatively stress-induced autologous RBCs compared to inflammatory monocyte 
phagocytosing un-stimulated RBCs (median monocyte/CFSE of 2.9% vs. 5.2% at 1 
monocyte to 25 RBCs ratio, p=0.0803). 
Stellenbosch University  http://scholar.sun.ac.za
iv 
 
 
Conclusion 
This study demonstrated a significant reduction in haemoglobin levels in untreated chronic 
HIV infection in a South African cohort. This anaemia was mirrored by significantly increase 
annexin V expression on RBCs. It was further shown that there was enhanced uptake of 
dying red blood cells by autologous monocytes. Treatments aimed at limiting oxidative stress 
or reducing immune activation may be beneficial in the management of anaemia in chronic 
HIV-1 infection. 
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Opsomming 
 
Inleiding 
Chroniese MIV-1 infeksie word gekenmerk deur uitgebreide inflammasie/immuun aktivering 
en ook deur anemie. Makrofage en neutrofiele produseer reaktiewe suurstof spesies (ROS), 
wat kan skade aan omliggende selle, insluitend rooibloedselle veroorsaak. Beskadigde 
rooibloedselle kan sterf deur apoptose (erythroptosis) of gemerk vir klaring deur 
monosiete/makrofage. In hierdie studie het ons ondersoek MIV-1-verwante bloedarmoede en 
erythroptosis in asimptomatiese, onbehandelde MIV-1 besmette individue en hoe dit verband 
hou met oksidatiewe stres en immuun aktivering. 
Materiaal en metodes 
Hierdie deursnee-studie ingesluit 44 chroniese MIV-1 besmette individue (CD4-telling> 200) 
en 33 ooreenstem beheer onbesmette individue. CD4-telling, virale lading, en hemoglobien 
vlakke gemeet is. Rooibloedselle (RBS) is gevlek met annexin V vir die bepaling van ex vivo 
vlakke van erythroptosis. Eritrosiete is ook onderwerp aan oksidatiewe stres (5 mm H2O2 of 
5mM askorbiensuur), in die teenwoordigheid of afwesigheid van N-asetiel cysteïne (NAC). 
Ten slotte, is ook RBS gevlek met CFSE, gestimuleer word met H2O2 en dan geïnkubeer met 
gesuiwerde monosiete opname van RBS te monitor. 
Resultate 
Asimptomatiese chroniese MIV-1 besmette individue het verminder hemoglobien vlakke in 
vergelyking met ooreenstem kontroles (12.9g/dL teen 14.1g/dL, p=0,0172). Die verminderde 
hemoglobien is weerspieël deur aansienlik hoër RBC-verwante annexin V basislyn 
uitdrukking in die MIV-1 besmette groep (13,4% vs 10.4%, p=0,0189). Annexin V uitdrukking 
verhoog in beide groepe wanneer dit gestimuleer word met H2O2. Hoewel NAC geïnhibeer 
veroorsaak oksidatiewe stres in beide groepe, die onbesmette groep vertoon sterker 
inhibisie. Die in vitro oksidatiewe spanning persentasie van apoptotisch RBS was aansienlik 
verminder in die kontrole groep (20±5,1% tot 15±4,4%, p=0,0063), maar nie die MIV-positief 
is 1 groep (18,3±5,0% tot 16±5.2 %. (p=0,0649)). Daar was 'n beduidende toename in die 
persentasie opruiende monosiete in die MIV-1 besmette groep, met die kontrole groep 
mediaan opruiende monosiet bestaande 5,3±3,8% in vergelyking met die MIV-positief is 1 
groep 8,3±3,5%, p=0,0054. In die MIV-1 besmette individue was daar 'n groter aantal 
inflammatoriese monosiet phagocytosing oxidatively stres-geïnduseerde lichaamseigen RBS 
in vergelyking met opruiende monosiet phagocytosing un-gestimuleer suspensie RBC 
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(mediaan monosiet/CFSE van 2,9% teen 5,2% op 1 monosiet tot 25 suspensie RBC 
verhouding , p=0,0803). 
Gevolgtrekking 
Hierdie studie dui op 'n beduidende afname in hemoglobien vlakke in onbehandelde 
chroniese MIV-infeksie in 'n Suid-Afrikaanse groep. Dit anemie is weerspieël deur aansienlik 
annexin V uitdrukking verhoog op RBS. Dit is verder getoon dat daar 'n verhoogde opname 
van die dood rooibloedselle deur lichaamseigen monosiete. Behandelings wat daarop gemik 
op die beperking van oksidatiewe stres of vermindering van immuun aktivering voordelig kan 
wees in die behandeling van anemie in chroniese MIV-1 infeksie. 
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Chapter 1: Introduction 
Acquired immune deficiency syndrome (AIDS) was first described more than three decades 
ago in Los Angeles (CA, USA) (Beyrer et al., 2012). Human immunodeficiency virus (HIV) is 
responsible for the development of AIDS and is the causative agent of the major AIDS 
pandemic. HIV-1 infection is characterized by a systemic pro-inflammatory milieu and 
persistent host immune system activation. The pro-inflammatory environment and chronic 
immune activation which is characteristic of chronic HIV-1 infection is also associated with 
anaemia (Weiss, 2009). Anaemia in HIV-1 may be due to either more rapid removal of 
erythrocytes from the blood circulation due to increased damage or death, or alternatively the 
bone marrow may be suppressed due to the inflammatory environment resulting in 
decreased erythrocyte production. Inflammation also promotes oxidative stress which is 
linked to cellular dysfunction and increased cell death. In the present study we have 
investigated the status of the erythrocyte compartment in untreated chronic HIV-1 infection, 
with a particular focus on the erythrocyte death (erythroptosis) and the sensitivity of 
erythrocytes to oxidative stress as a role player in anaemia in HIV-1 infection. 
It has been well described that HIV-1 infection facilitates the production of reactive oxygen 
species (ROS) (Agrawal et al., 2007). ROS in low to moderate levels are harmless but once 
they exceed optimal levels, they can become toxic to a cell. Glutathione (GT) is a type of 
anti-oxidant found in red blood cells that neutralises the low to moderate levels of ROS, 
however, higher levels of ROS depletes available glutathione and results in oxidative stress. 
Oxidative stress culminates in damage to the cell membrane, either directly or via the 
activation of caspases (Valko et al., 2007). N-acetyl-cysteine (NAC) antioxidant is the 
precursor molecule for glutathione. NAC is a free radical scavenger that has been shown to 
neutralise the damaging effects of ROS (Kamboj et al., 2010). In the current study, we 
investigated whether NAC could inhibit the damage sustained by RBCs in chronic HIV-1 
infection. 
Monocytes have an important function of clearance of dead, damaged or dying cells from the 
circulation host system. Damaged RBCs express phosphatidylserine at early stages of 
apoptosis and are thus primed for up-take by monocytes (Mikołajczyk et al., 2009)(Weiss, 
2009). Several studies have investigated phagocytic function in monocytes in HIV-1 infection, 
but none have investigated monocyte phagocytosed RBCs. In this study we investigated the 
different subtypes of monocytes and their phagocytic uptake capabilities of oxidatively 
stressed RBCs. 
The current study has thus examined the erythrocyte compartment in chronic HIV-1 infection 
at several levels. Initially the total red cell count and haemoglobin levels between healthy and 
HIV-1-infected individuals were compared. A notable incidence of anaemia in HIV-1-infection 
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then led to the investigation of erythrocyte death (erythroptosis). The ex vivo level of 
erythroptosis was increased in HIV-1 patients. Experiments involving in vitro oxidative 
stressing of erythrocytes indicated that the cells from the infected and uninfected individuals 
showed similar levels of sensitivity and equivalent increases in erythroptosis. Also, the 
antioxidant NAC, although effective in minimizing induced oxidative stress, could not reverse 
the damage that had occurred in vivo. Having established that erythrocytes in HIV-1 infection 
have higher baseline levels of annexin V expression, we then investigated how this impacted 
on the monocyte compartment, as splenic monocytes are the primary cell type involved in 
erythrocyte removal from the circulation. The monocytes in the HIV-1-infected group were 
skewed toward the inflammatory phenotype and this subset of monocytes also displayed an 
enhanced phagocytic ability. In the study we showed that the level of erythroptosis impacts 
on the resultant phagocytosis, thus implicating enhanced removal of red blood cells in the 
development of anaemia in chronic HIV-1 infection.  
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Chapter 2: Literature Review 
2.1. HIV-1/AIDS Epidemic Overview 
AIDS was first described on June 5, 1981 in Los Angeles (CA, USA), but the causative viral 
agent was only discovered two years later (Beyrer et al., 2012). In the original description of 
HIV-1 infection, patients showed symptoms of Pneumocytis carinii pneumonia (PCP), a rare 
opportunistic infection that was known to occur in people with significantly compromised 
immune systems (Helweg-Larsen et al., 2009). The causative virus was isolated 
independently by Robert Gallo and Luc Montagnier in 1983 (Fauci, 2008). Human 
immunodeficiency virus (HIV-1), as it came to be known, originated from simian 
immunodeficiency viruses (SIV) in chimpanzees (cpz) (Wertheim et al., 2009). The  disease 
was first reported mainly in homosexual males in 1983 but within a decade the heterosexual 
epidemic came to predominate worldwide (Beyrer et al., 2012). HIV consists of two subtypes: 
HIV-1 and HIV-2. HIV-1 originated from SIVcpz of central African chimpanzees, whereas 
HIV-2 originated from SIVsm of sooty mangabeys (sm) (Wertheim et al., 2009). 
The HIV-1 and HIV-2 viruses each have several subtypes. HIV-1 is divided into the following 
sub-groups M (major); O (outlier) and N (non-M/non-O). HIV-2 is divided into eight groups 
from A-H. The group M of HIV-1 is mainly responsible for the epidemic (and includes nine 
subtypes: A-D, F-H, J and K) (Wertheim et al., 2009; Tebit et al., 2011). HIV-1 infection in  
humans originated from  cross-species infection by  SIV, possibly due to contact with 
infected animals (bites, scratches) or contaminated meat (Worobey et al., 2008).  
HIV-1 infection represents one of the most severe infectious disease of the 20th century and 
is responsible for multiple human deaths (Volberding et al., 2010). In 2011 HIV-1 was 
responsible for approximately 1.7 million HIV-1 related deaths (UNAIDS, 2012). HIV-1 
transmission can be either horizontal or vertical. Vertical transmission occurs from HIV-1-
infected mothers to their unborn infants during pregnancy or during the birth process. 
Horizontal transmission is mainly due to sexual contact. Other horizontal transmitting factors 
contributing to HIV-1 infection included contaminated needles used during intravenous drug 
administration, and contaminated blood used for blood transfusions (Khan et al., 2007). AIDS 
is the end stage of untreated HIV-1 infection.  
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Figure 2.1. Prevalence of HIV-1 infection worldwide (2010).The world map represents the estimated 
prevalence of the 34 million individuals infected by HIV-1 at the end of 2011 (UNAIDS 2012). The 
darker the colour the greater the prevalence rate (http://maps.aidsalliance.org/map/global/ 
2010/prevalence/) 
 
Even though HIV-1 infection occurs worldwide, Sub-Saharan Africa, which includes only 3% 
of the world population, represents 69% of the global HIV-1 positive population (Lurie et al., 
2010). Sub-Saharan Africa also has the highest prevalence rate in the world with adult 
prevalence  of more than 15% (Lurie et al., 2010) as indicated in Figure 2.1 above. 
People infected with HIV-1 can live approximately 11 years without anti-retroviral treatment 
(ART) and approximately 23 years on highly active (combination drug) antiretroviral therapy 
(HAART) treatment before developing AIDS or before dying (Harrison et al., 2010). It has 
been estimated that there were 34 million people globally living with HIV-1 at the end of 
2010. Only 6.6 million people were on ART from the 14.2 million people that were eligible to 
receive treatment in low to middle income countries at the end of 2010 according to the 2011 
report released by the UNAIDS (http://www.unaids.org/en/resources/presscentre/ 
pressreleaseandstatementarcHIV1e/2011/november/20111121wad2011report/). 
HAART treatment can suppress viral replication of HIV-1 to such an extent that it is 
undetected by standard laboratory assays. The lower viral load results in lower levels of 
immune activation and decreased inflammation. If the use of HAART treatment is disrupted, 
the viral load may increase drastically (rebound effect) leading to recurrence of higher levels 
of immune activation and inflammation. 
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2.2 HIV-1 virus 
2.2.1. Structure 
HIV-1 is a retrovirus (family Retroviridae), belonging to the genus Lentivirus. It is a small 
enveloped ribonucleic acid (RNA) virus. HIV-1 consists of an inner cone-shaped core and a 
spherical matrix. The HIV-1 envelope lipid bilayer supports the gp41 glycoprotein (Gp) which 
is embedded within the membrane. The gp120 envelope glycoprotein is situated above and 
attached to the gp41 envelope glycoprotein. The combined structural unit comprising  gp41 
and gp120 is also  referred to as the gp160 (Chakrabarti et al., 2011).The p17 matrix protein 
is located beneath the lipid membrane, the structural component of the matrix capsid which 
encloses  the core of the virus. The viral core structure is composed of p24 protein. The 
capsid proteins surround and protect the two single RNA strands and reverse transcriptase 
(RT) enzyme of the virus (Lever, 2009) as indicated in Figure 2.2. 
 
Figure 2.2. Structure of the HIV-1 virion. The HIV-1 virus RNA is surrounded by lipid bilayer containing 
glycoproteins gp41 and gp120, protecting it from immune attack before entering the cell. The p17 
matrix protein and p24 capsid proteins (http://www.niaid.nih.gov/topics/HIV1aids/ 
understanding/biology/Pages/structure.aspx). 
 
The HIV-1 genome consists of only nine genes and is approximately 9kb in length. The nine 
genes viz. gag, pol, vif, vpr, vpu, tat, rev, env and nef, each play a critical role either in the 
structure of the virus or in the infection, replication and/or exocytosis processes (Watts et al., 
2009). The nine genes are categorized into three different groups i.e. structural (gag, pol and 
env), regulatory (tat, rev and nef) and accessory (vif, vpr and vpu) genes. The arrangement 
of HIV-1 genes is illustrated in Figure 2.3. 
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Figure 2.3. Diagram of the HIV-1genome.The HIV-1 genome consists of 9749 nucleotides. The 
genome is comprised of 9 genes (gag, pol, vif, vpr, vpu, tat, rev, env and nef) all having specific 
functions during HIV-1 infection, replication and spread (Watts et al., 2009). 
 
HIV-1 virus infects cells in a slow, continuously progressive manner. Like all retroviruses, 
HIV-1 has a unique way of replicating involving reverse transcription which is shown in figure 
2.4 and discussed in more detail below. 
 
Figure 2.4. A schematic representation of the HIV-1 viral life cycle. HIV-1 binds to the CD4 surface 
marker and chemokine co-receptors (CCR5/CXCXR4) of the T lymphocytes. Toll-like receptors (TLR) 
of the T cell detects various forms of the viral infection and initiates an immune response. TLR3 
recognises double stranded RNA (dsRNA), TLR7/8 recognises single stranded RNA (ssRNA) and 
TLR9 recognises double-stranded linear DNA (dsDNA) of the virus (Liu et al., 2008; Qu et al., 2009; 
Iwasaki et al., 2010). The virus goes on integrating the provirus DNA into the host DNA, replicating 
and finally exiting the cell through exocytosis. The virus repeats these steps in other uninfected cells 
(Mogensen et al., 2010). All these steps of the life cycle are explained below. 
 
2.2.2. HIV-1 replication 
2.2.2.1. Entry 
The HIV-1 virion targets cells expressing the CD4 surface molecules (viral receptor) and one 
or more chemokine co-receptors (CCR5/CXCR4) (Chun et al., 2012). These receptors define 
HIV-1 cell tropism. The main cell targeted during established HIV-1 infection is the 
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CCR5+CD4+ T lymphocyte a subset of T cells which is consequentially drastically reduced by 
HIV-1 infection (Funderburg et al., 2012). It is noteworthy that mucosal CD4+ T cells consist 
predominantly of memory CD4+ T cells which express the HIV-1 co-receptor CCR5 and 
represent an activated status (Brenchley et al., 2004). The envelope glycoprotein gp120 on 
HIV-1 interacts with CD4 surface marker on the T lymphocyte binding with a high affinity of 
28 nM (Dey et al., 2009). The envelope glycoprotein gp120 also attaches to the chemokine 
co-receptors CCR5/CXCR4 on the T lymphocyte (Briz et al., 2006). The binding activates the 
gp41 glycoprotein allowing it to insert a terminal fusion peptide into the cell membrane of the 
T lymphocyte.  The gp41 glycoprotein and terminal fusion peptide form a six-helix bundle 
formation allowing membrane fusion to occur. When fusion of the membranes is complete, 
the nucleocapsid is released into the cytoplasm of the T lymphocyte illustrated in Figure 2.5 
(Wilen et al., 2012). 
 
Figure 2.5. Attachment and entry of HIV-1 via GP120-CD4 binding. The HIV-1 attaches itself to CD4 
positive cells via its gp120 protein. The gp120 protein can also bind to the CXCR4 or CCR5 
chemokine co-receptors to gain access to the cell (Wilen et al., 2012). 
 
2.2.2.2. Reverse Transcription and integration 
Once inside the cell the HIV-1 enzyme known as reverse transcriptase, copies a single 
stranded RNA into a complementary DNA (cDNA) molecule. This double stranded viral DNA 
is then transported to host cell nucleus where it is integrated into the host DNA by a viral 
enzyme integrase (Zheng et al., 2005). The integrated viral DNA can be transcribed and 
translated when the host cell is activated and host cell gene transcription is activate 
(illustrated in Figure 2.6.). 
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2.2.2.3. Transcription 
Tat intensifies the HIV-1 transcription in infected CD4+ T lymphocytes. The HIV-1 Tat protein 
is responsible for placing the cellular positive transcription elongation factor b (P-TEFb) onto 
the integrated proviral DNA. The P-TEFb stimulates transcription by phosphorylating the C-
terminal domain of the RNA polymerase II (RNAPII) (Trono et al., 2010). The transcription of 
the provirus DNA produces viral messenger RNA (mRNA). The viral mRNA is translated into 
viral structural proteins and the viral enzyme RT within in the host cell cytoplasm (Jeang, 
2012) illustrated in Figure 2.6. 
 
2.2.2.4. HIV-1 assembly and budding 
The assembly of the viral structural proteins and core particles occurs at the plasma 
membrane of the host cell. Gag plays a major role in the packing of viral RNA, forming of 
spherical particles by linking proteins and assembly of the virion. All of these occur at the 
same time. Once the virus is assembled it is released from the plasma membrane by the 
endosomal sorting complexes required for transport (ESCRT) machinery. Viral particles exit 
the cell by budding, a process in which the virus acquires its outer envelope. New virions are 
thus set free to infect other nearby cells (Sundquist et al., 2012) illustrated in Figure 2.6. 
 
Figure 2.6. Representation of the production of a new HIV-1virion (reverse transcription, integration, 
transcription, assembly and budding) (Sundquist et al., 2012). 
 
2.3. HIV-1 Pathogenesis 
There are three phases in the pathogenesis of the HIV-1 infection, namely acute phase (also 
termed viremic), chronic phase (or latent) and late phase (full-blown AIDS). The first step in 
the pathogenesis process is the targeting and infection of  CD4+ T cells, leading to their 
depletion which is a characteristic feature of the acute phase (McMichael et al., 2010). A 
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second step which begins simultaneously to the first and which becomes amplified and 
defines the chronic phase of infection is immune system activation (Boasso et al., 2008). A 
third major step is the  dysfunction and exhaustion of the immune system ultimately leading 
to impairment, opportunistic infections, malignancies and  eventually  death (Cassol et al., 
2010). The three phases are discussed in more detail below. 
 
2.3.1. Acute HIV-1 pathogenesis phase (viremic) 
The acute HIV-1 phase extends from viral entry or the detection of the viral RNA until the 
production of HIV-1 specific antibodies approximately 3-4 weeks from day of infection. These 
HIV-1 specific antibodies are indicative of the development of a functional humoral immunity.  
Initial invasion of the host triggers localized inflammation and activation of the innate immune 
system. Resident cells initially detect the presence of the virus and initiate the recruitment of 
additional lymphocytes, monocytes (macrophages) and other cells to the site of infection and 
localized inflammation. These recruited cells are in turn targeted by the virus for infection 
(Mogensen et al., 2010). Initial infection usually occurs via the genital tract from where it 
spreads to secondary lymphoid organs after about a week. These secondary lymphoid 
organs include draining lymph nodes (LN) and gut-associated lymphoid tissue (GALT). It is 
unknown whether infection of the GALT is due to cells migrating from the LN and thus 
carrying virus there or by direct viral spread after release from infected cells in the LNs (Yan 
et al., 2011). The GALT is a major storage site for lymphocytes. The majority of these T 
lymphocytes are activated effector memory CD4+ T cells expressing the chemokine 
receptors CCR5 (Chun et al., 2012). HIV-1 replicates rapidly in the GALT and then plasma 
viraemia peaks between days 21-28 of infection. This rapid replication in the GALT leads to 
the destruction of the reservoir of helper T cells located there. The destruction of the 
reservoir helper T cells is irreparable in the GALT but circulating CD4+ T cell numbers are 
restored to almost normal levels in certain cases (Mogensen et al., 2010). During the acute 
stage HIV-1 integrates itself into the DNA of some resting memory T cells and then enters 
dormant (non-replicative) stage. This dormant stage is known as viral latency and is an 
important adaptive mechanism of HIV-1 to escape the immune system (Cohen et al., 2011). 
These resting cells also serve as viral reservoirs. The viral load decreases after 12-20 weeks 
as HIV-1 antigen specific CD8+ cytotoxic T lymphocytes (CTL) become active and eliminate 
infected cells and aid in establishing control of the infection (Mogensen et al., 2010) 
illustrated in Figure 2.7.  
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2.3.2 Chronic HIV-1 phase (latent) 
This stage of the HIV-1 infection begins after the viral load starts decreasing (and when CD4 
count begins to recover), and also when HIV-1 specific antibodies are first detected. Patients 
not on any form of treatment can live approximately 11 years in the chronic phase, whereas 
those on ART treatment can live approximately 23 years (Harrison et al., 2010). The defining 
concepts for chronic HIV-1 infection are: a low stable viral load (that is slowly increasing) 
resulting in continued enhanced immune activation; low mucosal CD4+ count and a relatively 
high (but decreasing) circulating CD4+ T cell count; stable CTL numbers, but also slowly 
decreasing as viral load increases over time (Ford et al., 2009; Mogensen et al., 2010). 
Increased immune activation and increased viral load leads to the depletion of CD4+ effector 
memory cells and also an accelerated cell turnover. The accelerated cell turnover produces 
naïve and central memory T cells to compensate for the depletion of the effector memory T 
cells in the gut. These cells are not very efficient in playing the role of the depleted CD4+ 
effector memory T cells (Brenchley et al., 2004).  
The naïve and memory CD4+ T cells that are produced express CCR5, thus resulting in 
more cells being available for HIV-1 infection (Picker et al., 2005). The depletion of the CD4+ 
effector memory cells in the GALT also results in damage to the mucosal barrier. The 
mucosal barrier can no longer effectively constrain the natural flora in the gut. Gut bacteria 
(microbiota) and microbial products such as lipopolysaccharide (LPS) translocate into the 
peripheral blood (Haas et al., 2011). The LPS contributes to the on-going chronic immune 
activation during HIV-1 infection by stimulating monocytes and other innate immune cells via 
the TLR4 (Seki et al., 2012). HIV-1 constantly evolves to escape immune defences by 
undergoing multiple mutations. Once the CD4+ CCR5+ T cells become low the viral 
mutations may also change the cellular tropism of the virus from CCR5-tropic to CXCR4-
tropic or dual tropic (CCR5 and CXCR4). Naïve/ memory T cells and monocytes/ 
macrophages expressing CXCR4 then also become targets for infection (Joshi et al., 2011). 
During chronic infection the lymphoid tissue is also damaged by the virus. The damage also 
leads to the dysfunction of the thymus which results in insufficient/ dysfunctional T cell 
production (Ofotokun et al., 2012) illustrated in Figure 2.7.  
 
2.3.3 Late phase (AIDS) 
The development of AIDS is due to the continued depletion of the CD4+ lymphocytes until a 
minimum threshold is reached (Joshi et al., 2011). An effective immune response and 
immune defences in general are largely dependent on these lymphocytes. The dysfunction of 
immune defences gives way to opportunistic infections and malignancies, eventually leading 
to the death of the infected host (Rockstroh et al., 2010). 
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Figure 2.7. Representation of the immune system at the acute and chronic stages of HIV-1 infection 
leading to the development of AIDS. (1-2) Initiation of innate immune system is trying to prevent HIV-1 
infection, (2-3) during inflammation numerous cells including activated T lymphocytes are recruited 
which are targeted to the virus, (3-4) viral load decreases to low levels at the start of chronic HIV-1 
infection, (4) the persistent immune activation upheld by the HIV-1 infection and opportunistic 
infections leads to the development of AIDS (Mogensen et al., 2010). 
 
2.4. Immune response in HIV-1 infection (innate, humoral and cell-mediated). 
2.4.1. Innate immunity 
Innate immunity includes barrier cells (such as epithelial cells), phagocytes (dendritic cells 
(DCs), monocytes and macrophages) and natural killer (NK) cells. These are the first line of 
defence against pathogens. These cells have both surface and intracellular  pattern 
recognition receptors (PRRs), which bind to pathogen-associated molecular patterns 
(PAMPs) (Yan et al., 2011; Vivier et al., 2011). PRR engagement leads to cellular activation 
and enhancement of function. Macrophages will engulf pathogens while NK cells will kill 
infected cells.  Infected cells that are activated, damaged or killed as a result of infection or 
early immune activity, release cytokines which in turn amplify inflammation. The on-going 
inflammation results in  recruitment of monocytes and neutrophils to sites of infection but also 
begins the initiation of acquired immunity when dendritic cells migrate to LNs to initiate 
antigen-specific immunity (Gonzalez et al., 2010). 
2.4.2. Humoral Immune Response 
The humoral immune response is not very effective in controlling HIV-1 infection (Alter et al., 
2010). HIV-1 causes B cells to produce large amounts of antibodies as evident by 
hypergammaglobulinemia, but these antibodies are not particularly effective. During the 
acute phase non-neutralizing antibodies that bind directly to the gp41 glycoprotein of HIV-1 
are produced. Soon afterwards, additional non-neutralizing antibodies are produced that bind 
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directly to the gp120 glycoprotein. These non-neutralizing antibodies are not very effective in 
reducing HIV-1 infectivity (Nicely et al., 2010). Autologous neutralizing antibodies (NAbs) are 
only produced weeks to months after initial infection which is too late to effectively neutralize 
infection, resulting in largely uncontrolled infections. The virus can also escape the NAbs by 
rapid mutation of the gp120 glycoprotein resulting in changing of antigenic determinants 
(Alter et al., 2010). 
 
Figure 2.8. Representation of antibody response to HIV-1 at different stages. (A) Non-neutralizing 
antibodies responds to the gp41 of HIV-1: (B) Non-neutralizing antibodies respond to the gp120 of 
HIV-1 soon afterwards: (C) autologous neutralizing antibodies (NAbs) specific for HIV-1 are produced 
weeks to months after initial infection: (D) the virus mutates the gp120 in order to escape the Nabs: 
(E) some individuals produce Nabs for numerous gp120 mutations and is known as broadly 
neutralizing antibodies (bnAbs) (Alter et al., 2010). 
 
2.4.3. Cell-mediated immune response 
Unlike the humoral immune response that mediates its function by producing antibodies (see 
section 2.4.2), the cell-mediated immune response activates antigen specific T cells (CD4 
and CD8) (Karanam et al., 2009). Cell-mediated immunity is very important in the control of 
HIV-1 infection, as evidenced in animal experiments where adoptive transfer of CD8+ CTL to 
monkeys conferred protection. Cells that are infected with HIV-1 will present antigens on 
their cell surface via major histocompatibility complex (MHC) class ɪ, thereby enabling 
cytotoxic CD8 T cells to recognize and kill them (via apoptosis induction) (Vivier et al., 2011).  
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2.5. HIV-1-associated immune activation and apoptosis 
Individuals infected with HIV-1 display elevated expression of markers of activation (both 
soluble (serum) and cell-associated (e.g. CD4+, CD8+, B cells, etc.)). These cells often also 
express elevated markers of apoptosis (Brenchley et al., 2004). Pro-inflammatory cytokines 
(TNF-α, IL-1 and IL-6) are increased during immune activation (Seidler et al., 2010). 
Increased CD8+ CTL activation also occurs which leads to higher expression of the 
activation marker CD38 on these cells. This marker has been correlated with HIV-1 disease 
progression (Barbour et al., 2009). Untreated HIV-1 infected individuals display a high 
immune activation status and depletion of CD4+ T cells (Zeng et al., 2011). The activation of 
the immune system produces a pro-inflammatory environment facilitating the replication of 
HIV-1. Increased replication leads to increased infection of host immune cells (primarily 
CD4+ T cells) contributing to the apoptosis of these cells. The apoptosis of these cells can 
occur directly or indirectly by mechanisms such as pro-inflammatory cytokines, viral peptides 
and other co-infections (Kirchhoff, 2009).  
In addition to the well described changes in immune cells in chronic HIV-1 infection, changes 
in other compartments are known. Anaemia is a common complication in chronic HIV-1 
infection. HIV-1-associated anaemia is the result of changes in the erythrocyte population of 
the infected host. As this study has focused on erythrocytes in chronic HIV-1 infection, some 
background is provided below. 
 
2.6. Red Blood Cells (RBCs) 
In 1668 the first red blood cell (RBC) was observed and described by the Dutch biologist and 
microscopist  Jan Swammerdam (Mohandas et al., 2008). RBCs form the majority (±45%) of 
whole blood. RBCs live approximately ±120 days (Bratosin et al., 2009). Healthy RBCs have 
a biconcave shape that is necessary in small, tight and high force spaces. This shape allows 
for minimal membrane bending energy requirements needed to squeeze through these areas 
(Kaoui et al., 2009). Erythrocytes originate from hematopoietic stem cells in the bone 
marrow. Five differentiation stages occur before the erythrocyte stage is reached. 
Hematopoietic stem cells generate pro-erythroblasts, which in turn give rise to erythroblasts, 
normoblasts, reticulocytes and eventually erythrocytes (illustrated in Figure 2.9). The 
progressive decrease in size and disappearance of the nucleus leaves an enucleated mature 
erythrocyte with a diameter of approximately 7-8µm (illustrated in Figure 2.10). Erythrocytes 
have one distinct surface marker on the cell membrane CD235a (Glycophorin A) (Lu et al., 
2008). Glycophorin A is a sialoglycoprotein (Berahovich et al., 2010). The unique shape of 
erythrocytes is believed to be caused by glycophorin A (Karsten et al., 2010). Erythrocytes 
have two major functions viz. transporting oxygen to muscles and organs and transporting 
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carbon dioxide from muscles and organs back to the lungs (Pittman, 2010)(Maitra et al., 
2011). In addition to their role in gaseous transport and exchange, they also play a role in 
coagulation and haemostasis (Zwaal et al., 1997). 
 
Figure 2.9. Schematic representation of erythrocyte differentiation from haematopoietic stem cell. The 
five stages prior to emergence of the mature erythrocyte are illustrated (Lu et al., 2008). 
Figure 2.10. Scanning electron micrographic representations of erythrocytes.Erythrocytes are some of 
the smallest cells in the human body. Mature cells reach a width of 2µm and lengths of between 7-
8µm. Cells have biconcave shape illustrated in Figure (A) from a top view and a cigar shape when 
viewing the cells from the side as in Figure (B) (Mohandas & Gallagher, 2008). 
 
2.7. HIV-1 associated anaemia 
RBCs contain the oxygen carrier molecule haemoglobin (Hb) which is also a marker of RBC 
compartment integrity. The integrity of the red cell compartment is also measured by the 
haematocrit (Hct), or packed cell volume (PCV). Anaemia is defined as either Hb or Hct  
below the normal level (Hb<13 g/dl and Hct<0.4 L/L) for age and gender (Quintó et al., 2006; 
Meidani et al., 2012). Anaemia has many different underlying causes such as iron deficiency 
or vitamin B12 folate deficiencies. In addition, anaemia is commonly found in individuals with 
diseases associated with chronic immune activation or inflammation, which is termed 
anaemia of chronic disease (ACD). HIV-1 infected individuals also develop chronic immune 
activation/inflammation and therefore the development of an associated anaemia is not 
unexpected and has been well described (Weiss, 2009). Continued immune activation leads 
to chronic production of several monocyte or neutrophil associated molecules, including 
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ROS. Unresolved inflammation thus alters the localized milieu (especially within lymphoid 
tissues) (Geissmann et al., 2010). Anaemia in chronic HIV-1 may be related to unresolved 
inflammation and excessive ROS leading to RBC death. Based on Hb data in two 
independent studies it was found that individuals not on HAART treatment (i.e. treatment 
naïve) had a prevalence of anaemia of approximately 40%, whereas  individuals on HAART 
treatment had a prevalence of 71% (Mildvan et al., 2007; Meidani et al., 2012). 
 
Figure2.11. The blood picture on the left illustrates the amount of RBCs in a healthy individual. The 
picture on the right illustrates a reduced amount of RBCs of an anaemic individual. 
http://www.pharmaceutical-networking.com/merck-mk-2578-for-treatment-of-anaemia-in-patients-
with-kidney-disease/ 
 
Anaemia is a common problem in HIV-1-infection and has many underlying causes 
(Omoregie et al., 2008). Chronic immune activation/inflammation is a key driving force in the 
progression to AIDS and is responsible for several complications associated with the 
infection. Anaemia which is the decrease of Hb (or loss of erythrocytes) can be due to: (1) 
increased RBC destruction; (2) increased up-take of prematurely aged or damaged RBCs by 
activated monocytes; and (3) decreased RBC production by the bone marrow (BM) (Ganz, 
2006). Chronic inflammation results in both the production of hydrogen peroxide (H2O2) by 
various cells (e.g. neutrophils and macrophages) and the depletion of antioxidants such as 
glutathione (Fu et al., 2010). Increased levels of ROS are thus the by-product of on-going 
inflammation and this has an impact on many cellular components, in particular the 
phospholipid bilayer of cell membranes. RBCs are also affected by ROS resulting in 
erythroptosis (Agrawal et al., 2007).  
Other chronic diseases, such as rheumatoid arthritis, produce a similar chronic inflammatory 
environment to that found in HIV-1 infection with the production of pro-inflammatory 
cytokines. IL-6 produced during a condition such as rheumatoid arthritis, inhibits the 
production of the hematopoietic growth factor erythropoietin (EPO) thus suppressing the 
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bone marrow production of erythrocytes and contributing to the development of anaemia 
(Raj, 2009; Steele et al., 2012). During HIV-1 infection IL-6 is also produced thus also 
resulting in bone marrow suppression of erythrocyte production (Raj, 2009). Other factors 
may also be involved in contributing to the development of anaemia in these individuals. The 
iron located in erythrocytes could facilitate the replication of the HIV-1 and depletion of iron 
and resultant anaemia may be a side-effect of the  promotion of  cellular infection (Johnson 
et al., 2012). Enhanced removal of RBCs in HIV-1 infection could also be due to elevated 
apoptosis or enhanced phagocytosis, or both (Cambos et al., 2011). Ineffective production of 
RBCs by the bone marrow due to HIV-1-related dysplasia may also be a  cause (Meidani et 
al., 2012). Another mechanism of anaemia induction is the production of antibodies against 
RBC antigens which then cause autoimmune haemolytic anaemia. These antibody-coated 
RBCs are more rapidly removed from the system by splenic macrophages (Bain, 1997). 
ARV therapy can directly impact on anaemia in both a positive and negative way. In a 2005 
study in Nigeria HAART was observed to increase haematocrit and haemoglobin levels in 
HIV-1 infected individuals suffering from anaemia. HAART consisted of a combination of 
nevirapine + stavudine + lamivudine (Odunukwe et al., 2005). In a 2008 study, also in 
Nigeria, it was found that HAART did not rectify anaemia owing to the fact that HAART in this 
study consisted of nevirapine + stavudine + zidovudine. The use of zidovudine instead of 
lamivudine has been linked to the development of anaemia. It has been suggested that 
zidovudine has a toxic effect on the bone marrow cells and could hinder the efficient 
production of haemoglobin as well as the transcription of the globin gene (Omoregie et al., 
2008). Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and the other 
HAART drugs in this combination are nucleoside analog reverse transcriptase inhibitors 
(NRTI). It has been reported that HIV-1 patients suffering from anaemia are at a significantly 
higher risk for reduced survival (Odunukwe et al., 2005). HAART drugs are chosen because 
they are effective against HIV-1; however, the development of anaemia may be a significant 
side effect of these drugs. 
2.8. Monocytes 
RBCs live for a short period of time (see section 2.6.) before they die or apoptose. The 
damaged/dying/dead cells need to be removed from the circulation. Monocytes have a 
distinct function of removing damaged/dying/dead cells from the circulation or from tissue. 
Monocytes are recruited to sites of infection during the innate immune response and are 
major producers of the pro-inflammatory cytokines tumour necrosis factor-α (TNF-α), 
interleukin-6 (IL-6) and interleukin-1 (IL-1) (Zimmermann et al., 2010). These cytokines are 
produced when the monocytes are activated. Activated monocytes (and also macrophages) 
remove damaged/dying cells such as RBCs in the spleen (Fendel et al., 2007; Swirski et al., 
2009). The innate immune functions of monocytes include immune defence in order to 
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protect the body from foreign invaders by phagocytosing infected cells and by the production 
of cytokines (Robbins et al., 2010). The adaptive immune functions include differentiation into 
macrophages or DCs and acting as antigen presenting cells, maintaining homeostasis and 
also repairing of damaged tissue (Auffray et al., 2009; Ziegler-Heitbrock et al., 2010).  
Monocytes make up a relatively small percentage of the human blood. The monocyte 
population comprises between 3-9% of the total leukocyte population (Ramoji et al., 2012). 
Monocytes are formed from myeloid precursors derived from the bone marrow (Seidler et al., 
2010). Monocytes are found abundantly in the spleen but also circulating in the peripheral 
blood stream in lower concentrations. The spleen plays a role as a site for storage of 
monocytes that can be deployed quickly to sites of injury/infection (Swirski et al., 2009). As 
mentioned above, the monocytes in the spleen also eliminate senescent and dead RBCs 
from circulation. Monocytes are located in the sub-capsular red pulp of the spleen (Swirski et 
al., 2009). Monocytes do not live long with a half-life of about three days (Mosig et al., 2009). 
Several major subsets of monocytes have been described. The major differentiation is 
between classical CD14+CD16- monocytes and inflammatory CD14+CD16+high monocytes. 
In certain schemes an intermediate monocyte population (CD14+CD16+low is included (Mosig 
et al., 2009; Zimmermann et al., 2010). The differentiation of the two major monocyte 
subsets by flow cytometry is illustrated in Figure 2.12 and a schematic illustration of the three 
monocyte subsets in the blood is shown in Figure 2.13. The classical monocyte population 
makes up approximately 95% of the total monocyte population in healthy individuals with the 
remaining 5% being inflammatory monocytes (Mosig et al., 2009). During chronic immune 
activation the inflammatory monocyte population increases significantly (Zhang et al., 2011).  
Monocytes have a cell diameter of 18-25µm, they are larger than lymphocytes and typically 
contain a kidney-shaped nucleus and intermediate granularity. Figure 2.14. shows a 
monocyte in a normal blood smear. Monocytes produce reactive oxygen species in low 
concentrations which act as signalling molecules that perform homeostatic functions. These 
functions include maintaining the cell cycle, metabolism and intercellular signalling 
transduction pathways (Federico et al., 2007).  
When persistent infection and inflammation occurs as in HIV-1 infection, the over production 
of ROS by monocyte may deplete the available glutathione levels and this impacts on 
surrounding cells, promoting their death (Federico et al., 2007).  
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Figure 2.12. The analysis of monocytes by flow cytometry. The monocytes were gated on in a FSC 
versus SSC dot plot. The density plot on the illustrates the two major  subsets of CD14+ monocytes 
examined  in this study (Ansari et al., 2012) 
 
Figure 2.13. Illustration of monocyte subsets located in peripheral blood. The three stage model is 
schematically illustrated and the defining surface markers are indicated (Ziegler-Heitbrock et al., 
2010). 
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Figure 2.14. Blood smear showing monocyte and erythrocytes.  Monocytes are bigger and complex 
when compared to erythrocytes. Erythrocytes are between 7-8µm in size compared to the monocyte 
that is between 18-25µm in size. Monocytes contain a nucleus and granules unlike erythrocytes. 
http://www.vetmed.vt.edu/education/curriculum/vm8054/labs/lab6/lab6.htm     
 
2.9 Reactive Oxygen Species (ROS) 
Inflammatory cells such as monocytes routinely produce ROS as part of their normal cellular 
metabolism. Oxygen (O2) is one of the key elements that humans need to survive and also 
the essential element of ROS. Oxygen circulates through the body and has various functions. 
Low to moderate levels of ROS are beneficial to the host. These low/ moderate levels of 
ROS play physiological roles in various cellular responses and protect the host against 
infectious agents (Valko et al., 2007). Homeostasis between the beneficial and/or harmful 
effects of intermediate species is crucial in living organisms (Federico et al., 2007).  
The balance between production and removal of ROS is mediated by antioxidants (e.g. 
superoxide dismutase (SOD), glutathione peroxidise, glutathione-S-transferase and 
glutathione (GT), etc.) that mop up these destructive molecules (Valko et al., 2007). The 
imbalance in redox status and the enhanced production of intermediate reactive species 
progressively consumes the antioxidant defences, leading the cells to develop oxidative 
stress (as illustrated in Figure 2.15). Cells such as RBCs can  respond to the oxidative stress 
either by enhancing their antioxidant potential (by increasing production of antioxidant 
molecules) or by activating cytoplasmic caspases that induce programmed cell death 
(apoptosis), which  in the case of RBCs is known as erythroptosis (Herrera et al., 
2001)(Bratosin et al., 2009).   
Phosphatidylserine (PS) is a phospholipid found on the inner leaflet of all cell membranes 
(including RBCs). When RBCs are exposed to sufficient levels of oxidative stress the PS will 
transfer to the outer leaflet of the membrane. It is unknown whether the shift of the PS from 
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the inner to the outer leaflet is a form of programmed apoptosis or whether the membrane 
fatty acids are being stimulated by the oxidative stress itself. This transfer of the PS on RBCs 
is a sign of early apoptosis (erythroptosis) (Berg et al., 2001). The oxidation or peroxidation 
of plasma membranes and other cellular structures, if unchecked, may culminate in the death 
of the cell and ultimately, could contribute to disease development. It is on this basis that 
oxidative stress is increasingly being implicated in the pathogenesis of multiple acute and 
chronic inflammatory human diseases (Lum et al., 2001)(Lang et al., 2004). 
 
Figure 2.15. Healthy RBCs versus oxidative induced RBCs. The picture on the left illustrates a normal 
RBC structure. The picture on the right hand side illustrates the RBC deformation due to oxidative 
stress caused by H2O2 stimulation (Ajila et al., 2008). 
 
2.10. Detection of erythroptosis 
During chronic conditions such as HIV-1 infection, various cells are damaged. These cells 
need to be eliminated in order to maintain homeostasis. Apoptotic cells display PS on the 
external surface of the cell membrane allowing them to be phagocytosed following detection 
by scavenger receptors on monocytes/macrophages. Apoptosis can be measured by 
determining the level of  binding of annexin V to the exposed PS on damaged cells 
(Demchenko, 2012). 
Annexin V is a  molecule that binds specifically to PS on cells membranes in a calcium 
dependent manner (Yan et al., 2008). Annexin V can be conjugated to a fluorescent marker 
such as FITC. FITC is excited at a wavelength of 488nm. The annexin V bound to the PS on 
apoptotic cells can then be measured by flow cytometry as illustrated in Figure 2.16. 
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Figure 2. 16. Illustration of PS (circles with negative signs in them) transferring to the outer leaflet of a 
cell membrane and is a sign of early apoptosis. Annexin V is a calcium dependant antibody that is 
conjugated to a fluorescent marker binding to the exposed PS and allows for detection by flow 
cytometry when excited with laser light (Demchenko, 2012). 
 
2.11. Hypothesis 
 The study hypothesis was chronic stable HIV-1 infection is accompanied by anaemia 
(decrease Hb.), due to elevated erythroptosis. The elevated erythroptosis is linked to 
ROS damage and may be reversible through antioxidant treatment. Finally, increased 
erythroptosis is linked to changes in monocyte subset distribution, with HIV-1 infected 
individuals having a predominance of phagocytic pro-inflammatory monocytes. 
 
2.12. Aims of study 
To investigate  
 The relationship of anaemia with red cell death (erythroptosis) 
 Compare Hb, Hct, RCC between HIV infected and uninfected groups 
 Measure levels of spontaneous (ex vivo) + induced erythroptosis in the two groups 
 Whether antioxidant (NAC) can rescue RBCs from erythroptosis in both groups 
 To determine relationship between RBC death, Hb and RBC parameters and immune 
activation status in the two groups 
 To assess autologous monocyte uptake of RBCs in the two groups 
 Total monocyte count vs. functional response 
 To compare classical vs. inflammatory monocyte response to RBCs and measure 
level of erythroptosis 
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3. Methodology  
3.1. Study Participants 
All donors were recruited from Emavundleni, a HIV Counselling, Testing and Prevention 
(HCT) Clinic, in Crossroads, Cape Town. The prevention clinic employs the national HCT 
testing algorithm with accredited rapid tests. Inclusion criteria: age >21 years; clinically 
asymptomatic with CD4 counts >200 cells/µl at initial screen. Not on antiretroviral therapy. 
Exclusion criteria: Concurrent infections, tuberculosis (TB) or anti-TB therapy. Ethical 
Considerations: The study was approved by the University of Stellenbosch Ethics committee 
HREC N07/09/197 and the University of Cape Town REC 417/2006 and performed 
according to the declaration of Helsinki. 
A total of 44 HIV-1 positive (HIV-1) and 33 matched HIV negative (negative control) whole 
blood samples were collected from the clinic. HIV-1 positive donors’ statuses were confirmed 
with the use of an ELISA rapid HIV+ test. Once HIV status was confirmed, donors were bled 
and CD4 count determined. Original CD4 determinations were performed by the clinic 
associated laboratory one month prior to blood collection for the current study. Donors with 
original absolute CD4 counts of above 200 cells/µl were included on the study. Donors were 
not on any antiretroviral (ARV) treatment (i.e. treatment naive). HIV-1 positive donors were 
re-assessed for CD4 count on the day of blood donation. There were 6 HIV-1 positive 
individuals who had a CD4 count <200 cells/µl when CD4 counts were measured on day of 
blood collection (i.e. 1 month after initial CD4 count). These 6 HIV-1 individuals were 
included within the study. All patients were also asymptomatic for other diseases with no 
underlying infections or conditions at the time of blood extraction. Donors were properly 
informed that their blood would be used for research purposes in the study and they signed 
consent forms presented to them in their mother tongue. Demographics of study participants 
are presented in Table 4.1 in the results section in chapter 4. 
 
3.2. Whole blood collection and Transport 
Whole blood was collected by venipuncture by a qualified nursing sister at the walk-in clinic. 
Both ethylenediaminetetraacetic acid (EDTA) 5ml and Sodium Heparin 10ml vacutainer 
tubes (BD Biosciences, San Jose, CA, USA) were used. A total of 15ml whole blood was 
collected from each donor. Blood tubes were transported to the laboratory by the clinic 
courier service. Bloods reached the laboratory within 3-4 hours of collection. At arrival at the 
laboratory the specimens were immediately processed. 
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3.3. Viral Load 
2.5ml EDTA blood was aliquoted and transferred to a sterile 5ml BD Falcon tube (BD 
Biosciences, San Jose, CA, USA) and centrifuged (Heraeus Megafuge 2.0 R, Germany) for 
10 minutes at 375xg at 20ºC (room temperature). Plasma (500µl) was aliquoted into a pre-
labelled sterile Eppendorf tube. Samples were then delivered by hand to the routine viral load 
testing laboratory in the Division of Medical Virology (NHLS, Tygerberg, Cape Town, South 
Africa) and samples were tested within 8 hours of blood collection. The Abbott RealTime 
HIV-1 viral load assay was performed on samples. This test has a detection range of 40 to 
10,000,000 copies/mL. HIV RNA levels in the plasma were quantitated by nucleic acid 
amplification. The assay is validated against a viral standard from the Virology Quality 
Assurance (VQA) Laboratory of the AIDS Clinic Trail Group and accredited by the World 
Health Organization (WHO). The assay is also South African National Accreditation System 
(SANAS) approved. SOP number HAE1455. 
 
3.4. CD4 Count 
EDTA blood (300µl) was aliquoted from the 5ml EDTA tube for CD4 count measurement. 
The BD MultiTEST™ CD3 FITC/ CD8 PE/ CD45 PerCP/ CD4 APC Reagent (BD 
Biosciences, San Jose, CA, USA) and TruCOUNT tubes (BD Biosciences, San Jose, CA, 
USA) were used for CD4 count determination. TruCOUNT tubes were labelled with study 
participant numbers. MultiTEST reagent (antibody mix) (20µl) was added into the bottom of 
the TruCOUNT tube containing a steel retainer, above the bead pellet. Pre-aliquoted EDTA 
blood (50µl) was then added to the tube. The tubes were vortexed and left to incubate for 15 
minutes at room temperature in a dark area. After incubation, 450µl of Fluorescent Activated 
Cell Sorter (FACS) lysing solution (BD Biosciences) was added, vortexed and again left to 
incubate for another 15 minutes at room temperature. Analysis of the sample was performed 
on a flow cytometer (Becton Dickinson FACSCalibur with MultiSET™ software). The CD4 
counts were validated to control samples (LymphoSure) purchased from Synexa Life 
Sciences (Cape Town, SA).This method is the standard CD4 standard operating procedure 
(SOP number VIRO 00016.5) used in the Division of Medical Virology, which has been 
accredited by SANAS.  
 
3.5. Full Blood Counts 
Full blood count (FBC) measurements were performed in the Haematology Division of the 
National Health Laboratories Services (NHLS Tygerberg Hospital, Cape Town, SA). EDTA 
blood samples were run through the Siemens ADVIA 2120 system, which uses 
cytochemistry and flow technology. FBC results and white blood cell (WBC) differential 
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parameters were collected from the machine printout. These measurements are also SANAS 
accredited. The FBC parameters relevant to this study included RBC count, Hb levels, 
haematocrit (HCT) levels and monocyte count and percentages (of total leukocytes) (SOP 
number GPL0866).  
 
3.6 CD38 expression on CD8 T lymphocytes labelling and gating 
3.6.1. CD8 T cell labelling 
CD38 expression on CD8 T cells was used as a marker for immune activation in this study 
(see Chapter 2 section 2.5.). Whole blood (50µl) from the 10ml heparin tube was aliquoted 
into a sterile 5ml BD Falcon tube (BD Biosciences, San Jose, CA, USA). An antibody cocktail 
was prepared containing the following antibodies (based on recommended volumes): 10µl 
CD3 (FITC), 10µl CD8 (PerCP) and 5µl CD38 (APC). All antibodies in this procedure were 
purchased from Becton Dickinson (BD Biosciences, San Jose, CA, USA). The antibody 
cocktail (25µl) was then added to each sample. Samples were incubated for 20 minutes in a 
dark area at room temperature. After incubation, 500µl lysing solution (BD Biosciences, San 
Jose, CA, USA) was added to each tube. Tubes were placed in a dark area and left to 
incubate for 15 minutes at room temperature. After incubation cells were washed by adding 
300µl staining buffer to each tube. Samples were centrifuged for 10 minutes at 300xg at 
20°C. Supernatant was removed and discarded. Pellet was re-suspended by adding 500µl 
staining buffer and was vortexed. Samples were analysed on the same day by flow 
cytometry (BD FACS-calibur, BD Biosciences, San Jose, CA, USA). 
 
3.6.2. CD8 T cell gating and analysis 
The total lymphocyte population in a FSC versus SSC dot plot was gated (G1=R1). Fifty 
thousand G1 gated events were gathered during the CD38/CD8 T lymphocyte acquisition. A 
second gate was created (G2=R2) on the CD3 positive population in a SSC versus CD3 plot 
generated from the G1 gated population. Expression of CD8 and CD38 (the 
activation/inflammation marker) were then measured in a two colour “quad stat” plot of CD8 
versus CD38 (Figure 3.3.).  
 
3.7. In vitro RBC preparation, stimulation with oxidative stressors, annexin V labelling 
and analysis 
3.7.1. Stimulation with oxidative buffers 
Sodium heparinised blood (10µl) was pipetted into 5ml BD Falcon tubes (BD Biosciences, 
San Jose, CA, USA) and was used to carry out each stimulation. Donor samples (13 
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negatives and 14 positives) were stimulated with 2 different oxidative stressors for varying 
time periods. The effects of the different oxidative stressors were evaluated. Un-stimulated 
cells (negative control) were incubated with Dulbecco’s Phosphate Buffered Saline (DPBS, 
contains no Ca2+ or Mg2+, Gibco, Invitrogen Corporation, UK), while test samples were 
exposed to either  hydrogen peroxide (H2O2) (final concentration of 5mM) or an ascorbic acid 
oxidative buffer (DPBS + 5mM sodium-L-ascorbate (Sigma-Aldrich, UK) + 0.4 mM copper (II) 
sulphates (Sigma-Aldrich, UK)) (Cambos et al., 2011). H2O2 or ascorbic acid oxidative buffer 
(AAOB) (10µl) was added to each tube containing 10µl blood as previously optimized in our 
laboratory (S. Loots, BSc Honours thesis, unpublished). Samples stimulated with 5mM H2O2, 
were incubated for 1 hour at 37ºC at 5% CO2. Oxidative buffer stimulations were carried out 
for three different time periods (30 minutes, 1 hour to 2 hours) at 37ºC at 5% CO2.  
 
After incubation, RBCs were washed by adding 500µl 1x annexin V binding buffer (ABB) 
(Biolegend) to each tube and centrifuged at 300xg for 5 minutes at room temperature. 
Supernatant was carefully removed without disturbing the pellet and supernatant was 
discarded. Cells were then stained with 2.5µl annexin V (FITC) (eBioscience, San Diego, CA) 
as recommended by manufacturer (see section 3.10). AAOB stimulation was discontinued 
after comparison of 27 samples (13 controls and 14 positive samples) as the level of red cell 
apoptosis was not significantly different to that induced by H2O2. Including the 27 samples 
stimulated with either H2O2 or AAOB an additional 50 samples were stimulated with H2O2 
alone after discontinuation of AAOB.  
 
3.7.2. Impact of the anti-oxidant NAC 
The impact of the antioxidant N-acetyl cysteine (NAC) on H2O2-induced stress was 
evaluated. Blood was incubated in the presence or absence (control) of various 
concentrations (2.5mM, 5mM and 10mM) of NAC (Sigma-Aldrich, UK) during stimulation with 
5mM H2O2 as described above in section 3.7.1. NAC was added to cells in 48 samples (20 
controls and 28 positive) with the three different concentrations of NAC indicated above. The 
NAC was added 30 seconds prior to H2O2 stimulation and then throughout the stimulation 
period. The same washing, staining procedures as previously described in section 3.7.1. and 
analysis procedures as described in section 3.13 were followed.  
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3.8. RBC purification, CFSE labelling, stimulation and measuring of up-take by purified 
monocytes 
3.8.1. Purification of RBCs from whole blood using Peripheral Blood Mononuclear Cell 
(PBMC) extraction method 
Whole blood (1ml) was aliquoted from a 10ml Sodium Heparin vacutainer tube (BD 
Biosciences, San Jose, CA, USA) and pipetted into a 15ml BD Falcon tube (BD Biosciences, 
San Jose, CA, USA) and diluted with 9ml DPBS. The 10ml Sodium Heparin tube containing 
the remaining 9ml whole blood was stored overnight at 4ºC in a refrigerator (K.I.C., South 
Africa) prior to monocyte purification as described in section 3.9. Initially 20ml Histopaque-
Ficoll® (Sigma-Aldrich, UK) was added to a 50ml Leucosep tube (BD Biosciences, San Jose, 
CA, USA) and centrifuged for 1 minute at 375xg at room temperature to ensure the 
Histopaque-Ficoll® was gathered underneath the frit. The 10ml diluted blood prepared above 
was added to upper level of the 50ml Leucosep tube (BD Biosciences, San Jose, CA, USA) 
and centrifuged for 10 minutes at 300xg at room temperature. Plasma was extracted and 
discarded with the use of a bulb pipette (BD Biosciences, San Jose, CA, USA). RBCs were 
removed from the bottom of the tube and transferred to a 5ml BD Falcon tube (BD 
Biosciences, San Jose, CA, USA). 1ml RPMI + 5% heat inactivated Fetal Bovine Serum 
(hiFBS) (PAA: The cell culture company, Piscataway, NJ, USA) was added to the tube. 
Tubes were placed overnight in an incubator (NUAIRE™, US AUTOFLOW CO2 Water-
Jacketed Incubator) at 37ºC and 5% CO2 concentration.  
 
3.8.2. RBC preparation including CFSE staining of RBCs and stimulation for 
phagocytosis 
Monocyte uptake of un-stimulated and H2O2-stressed RBCs was then investigated. RBCs 
were stained with 2.5mM Carboxyfluoresceinsuccinimidyl ester (CFSE, Invitrogen, CA, USA) 
prior to oxidative stress induction. Before stimulation with H2O2, purified RBCs were stained 
with the intracellular stain CFSE according to methods of Cambos et al., 2011. 200µl RBCs 
were pipetted into a 5ml BD Falcon tube and 200µl CFSE with a 2.5mM final concentration 
was added to the tube. Tube received a quick vortex to ensure proper mixing of cells and 
intracellular stain. The tube was then placed in a dark room and left to incubate for 15 
minutes at room temperature. After incubation stained RBCs were washed by adding 1ml 
Sep medium and centrifuged for 5 minutes at 300xg at room temperature. Supernatant was 
extracted and discarded and stained RBCs were removed and pipetted to sterile 5ml BD 
Falcon tube. 
 
Stained cells were washed by adding 500µl DPBS to each tube and then centrifuged at 
300xg for 5 minutes. Stained RBCs (7µl) were aliquoted and pipetted into adjusted volume of 
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DPBS in order to have a total of 250 000 cells and used as is for the un-stimulated RBC 
control experiments. The remaining RBCs were stimulated with H2O2 as previously described 
above see section 3.7.1. Stimulated cells were washed by adding 500µl DPBS to each tube 
and centrifuged at 300xg for 5 minutes at room temperature to ensure no further stimulation 
could take place. After washing, 7µl of stimulated RBCs were aliquoted and transferred to the 
same adjusted volume of DPBS as the un-stimulated to ensure the stimulated RBC dilution 
had the same concentration. These stained and pre-stimulated RBCs were added to purified 
monocytes obtained from the same donors (see section 3.9. below). 
 
3.9. Monocyte purification using a 2 step (enrichment plus positive selection) 
procedure 
3.9.1. Enrichment of monocytes by negative selection (RosetteSep).  
An illustration of this procedure is provided in figure 3.1. A. The 10ml Sodium Heparin tube 
containing the 9ml donor blood from section 3.8.1.was mixed before it was centrifuged for 10 
minutes at 375xg at room temperature. Plasma was discarded and 4ml of the blood was 
aliquoted to a 15ml BD Falcon tube (BD Biosciences, San Jose, CA, USA). RosetteSep® 
Human Monocyte Enrichment Cocktail (STEMCELL Technologies, North America) (200µl) 
was added and mixed with the 4ml whole blood and left to incubate for 20 minutes at room 
temperature. RosetteSep® Human Monocyte Enrichment Cocktail enriches the monocyte 
fraction by removing cells expressing CD2, CD3, CD8, CD19, CD56, CD66b, CD123 and 
glycophorin A (i.e. T and B lymphocytes, NK cells, neutrophils, RBCs, granulocytes and 
dendritic cells (DCs)), thus leaving an enriched monocyte population. 15ml Histopaque-
Ficoll® (Sigma-Aldrich, UK) was pipetted into a sterile 50ml BD Falcon tube (BD Biosciences, 
San Jose, CA, USA). The tube containing the 4ml blood was diluted with an additional 6ml 
medium consisting of DPBS + 2% heat inactivated (hi) FBS + 1mM EDTA referred to as Sep 
medium from now on.  
 
The 10ml diluted blood mentioned above containing the enriched antibody cocktail was 
extracted and carefully added to the tube containing the Histopaque-Ficoll® (Sigma-Aldrich, 
UK). Tubes were centrifuged at 375xg for 30 minutes at room temperature. The interface 
monolayer containing the monocyte enriched layer (7.5ml) was carefully removed and 
transferred to a sterile 50ml BD Falcon tube (BD Biosciences, San Jose, CA, USA). Sep 
medium (27.5ml) was added to the 50ml BD Falcon tube to give a final volume of 35ml. The 
tube containing the enriched monocytes underwent a wash step with centrifugation for 10 
minutes at 375xg at room temperature. The supernatant was discarded and the pellet was 
gently re-suspended in 4ml DPBS. 50µl cell suspension was aliquoted and stained with 50 µl 
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Turks staining solution (0.02% crystal violet, 7% glacial acetic acid in water)(Sigma-Aldrich, 
UK) and cells were counted under a light microscope (Nikon, Eclipse E200, Japan). The 4ml 
cell suspension was centrifuged for 10 minutes at 375xg at room temperature. The monocyte 
purity (see section 3.11.2) obtained was <60% using this method alone, therefore an 
additional positive selection procedure was also used, as discussed below. 
 
3.9.2. Purification of monocytes from the enriched monocyte fraction by positive 
selection 
An illustration of this procedure is provided in Figure 3.1. B. The enriched monocytes isolated 
during the RosetteSep® monocyte procedure (see section 3.9.1.) did not generate a 
sufficiently pure cell population therefore an additional purification technique was applied. 
After monocyte enrichment (see section 3.9.1.) the tube was centrifuged to form a cell pellet 
at the bottom of the tube containing the enriched monocytes. The supernatant was 
discarded. Sep medium (100µl) was added to the tube and pipetted up and down slowly to 
re-suspend the pellet. EasySep® Human CD14+ positive selection cocktail (STEMCELL 
Technologies, USA) (10µl) was added to the tubes as specified by the manufacturer. Tubes 
were incubated at room temperature for 15 minutes. After incubation, 5µl of magnetic-
nanoparticles (STEMCELL Technologies, USA) were then added and mixed as instructed by 
manufacturer. Tubes were inserted into specialized immunomagnets (STEMCELL 
Technologies, USA) made for use in this technique. Magnets were placed on a flat surface 
for 5 minutes. Magnets still containing tubes were inverted after 5 minutes to discard 
unattached cells (i.e. non- selected cells). Tubes were removed from the magnets and 2.5ml 
Sep medium was added in order to re-suspend cells adhering to the sides of the tube. Tubes 
were placed back into the magnets and the process repeated another 4 times ensuring no 
unwanted cells remained. After the fifth and final wash the tubes were removed from the 
magnets and cells were gently washed from the side of the tubes by adding 1ml Sep 
medium. The monocyte purity obtained after this method routinely exceeded 75%. 
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Figure 3.1. The two different methods used to obtain the highest possible monocyte purity from whole 
blood.The method on the left hand (A) is the enrichment of monocytes by negative selection 
(RosetteSep). The method on the right (B) is the purification of monocytes by positive selection 
following the enrichment step. 
 
3.10. Flow cytometry antibody cocktail preparation 
Antibody cocktails were prepared for (a) RBC apoptosis analysis (b) measuring monocyte 
purity (c) measuring phagocytosis of RBCs by monocytes and (d) measuring activation of 
cytotoxic T lymphocytes as a general marker of immune activation. Manufacturer, 
fluorochrome, clone and isotype details are shown in Table 3.1. All antibodies were kept in a 
4°C fridge (K.I.C., model, South Africa) and were placed on ice when in use. Cocktail 1 for 
RBC apoptosis analysis consisted of four markers: CD45 PerCP (leukocyte marker), CD235a 
APC (Glycophorin A; RBC marker), CD41a PE (platelet marker) and annexin V FITC 
(phosphatydilserine marker). Cocktail 2 measuring monocyte purity consisted of four 
markers: CD45 FITC (leukocyte marker), CD3 PE (T lymphocyte marker), CD16 PerCP and 
CD14 APC (monocyte/ macrophage markers). Cocktail 3 measuring CFSE stained RBC 
phagocytosed by monocytes consisted of two markers CD14 APC (monocyte marker) and 
CD16 PerCP (inflammatory monocyte/macrophage marker). Cocktail 4 measuring the 
activation of cytotoxic T lymphocytes consisted of three markers CD8 PerCP (lymphocyte 
marker), CD3 FITC (lymphocyte marker), and CD38 APC (activation marker). Staining 
procedures are explained in section 3.11.  
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RBCs were stained with cocktail 1 after stimulation of cells (see section 3.10.). In 
phagocytosis experiments RBCs were stained with CFSE before stimulation (see section 
3.8.2.). Monocytes were stained with cocktail 2 to measure the purity of monocytes isolated. 
CFSE stained RBCs were added to the monocyte stained with cocktail 3 to measure 
phagocytosis of dead/dying RBCs by monocytes.  
 
Antibody titrations were performed to determine the optimal volume of each monoclonal 
antibody required for this study. The final titrated volumes of individual antibodies are 
indicated in Table 3.1. The intracellular stain (CFSE) was diluted with 2ml PBS to obtain a 
final concentration of 5mM.  
 
Table 3.1. Antibodies used in this study. 
Cocktails Antibodie Fluorochrome Manufacturer Clone Type Host Final 
titration 
volume 
(µl) 
Cocktail 1 
RBCs 
CD45 PerCP BioLegend HI30 IgG1 Mouse 2.5 
CD235a APC eBiosciences HIR2/GA-
R2 
IgG2b Mouse 2 
CD41a PE eBiosciences HIP8 IgG1 Mouse 2.5 
Annexin V FITC eBiosciences N/A N/A N/A 2.5 
Cocktail 2 
Monocyte 
purity 
CD45 FITC BioLegend HI30 IgG1 Mouse 3 
CD14 APC BioLegend M5E2 IgG2a Mouse 4 
CD16 PerCP BioLegend 3G8 IgG1 Mouse 4 
CD3 PE BioLegend UCHT1 IgG1 Mouse 3.5 
Cocktail 3 
Monocyte 
phagocytosis 
CD14 APC BioLegend M5E2 IgG2a Mouse 4 
CD16 PerCP BioLegend 3G8 IgG1 Mouse 4 
Cocktail 4 
Immune 
activation 
CD3 FITC BD 
Biosciences 
UCHT1 IgG1 Mouse 10 
CD8 PerCP BD 
Biosciences 
SK1 IgG1 Mouse 10 
CD38 APC BD 
Biosciences 
HB7 IgG1 Mouse 5 
PerCP = Peridinin chlorophyll protein; APC = Allophycocyanin; PE = Phycoerythrin; FITC = 
Fluorescein isothiocyanate 
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3.11. Staining Protocol 
3.11.1. RBC staining with cocktail 1 (CD41a, CD45, CD235a and annexin V) to measure 
RBC apoptosis 
Antibodies were placed in a dark area on ice prior to staining procedure. RBCs were stained 
in 5ml BD Falcon tubes. After H2O2 stimulation, 10µl whole blood was washed. ABB (500µl) 
was added to tubes and centrifuged at 300xg for 5 minutes at room temperature. This 
washing step removed any unwanted H2O2 left in the tube and also provided calcium to the 
cells for annexin V antibody binding. Supernatant was removed and discarded. Both 
stimulated/un-stimulated whole blood was stained using cocktail 1: (see Table 1. section 
3.10.). Samples were incubated in the dark for 15 minutes at room temperature. After 
incubation, stained samples underwent another wash step, adding 500µl PBS and were 
centrifuged at 300xg for 5 minutes at room temperature to ensure that no unbound 
antibodies remained. Supernatant was removed and discarded. 500µl Staining buffer (0.4% 
Heat-inactivated Fetal Bovine Serum (Gibco, Invitrogen Corporation, UK) in PBS) was added 
to tubes followed by a quick vortex. Tubes were stored in the dark until acquisition on the 
flow cytometer.  
 
3.11.2. Staining of monocytes with cocktail 2 (CD45, CD3, CD14 and CD16) to measure 
purity and subset distribution 
Purified monocytes were stained with Turks solution (see section 3.9.1.) and counted under 
a light microscope in order to calculate how many cells were obtained within 4ml. Tubes 
containing purified monocytes were centrifuged for 15 minutes at 375xg at room 
temperature. Supernatant was discarded and pellet was re-suspended in 1ml PBS. The 
number of cells was then adjusted to 1X105 cells/ml. The tube containing the 1X105 cells/ml 
monocytes was stained using cocktail 2 (see Table 1. section 3.10.). Tubes were incubated 
for 15 minutes in a dark room at room temperature. 1ml Sep medium was added to tubes 
and tubes were centrifuged for 15 minutes at 375g at room temperature. Supernatant was 
removed and discarded and pellet re-suspended in 1ml Sep medium.  
 
3.11.3. Staining of monocytes with cocktail 3 (CD14 and CD16) to measure 
phagocytosis of CFSE labelled RBCs 
Purified monocytes were counted under a light microscope. Tubes containing purified 
monocytes were again centrifuged for 15 minutes at 375xg at room temperature. 
Supernatant was discarded and pellet was gently re-suspended in 1ml PBS. The number of 
cells/ml could then be adjusted to the volume 1X105 cells/ml. The adjusted volume was then 
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aliquoted and transferred to a sterile 5 ml BD Falcon tube. The tube containing the 1X105 
monocytes was stained using cocktail 3 (see Table 1. section 3.10.). Tubes were incubated 
for 15 minutes in a dark room at room temperature. 1ml Sep medium was added to tubes 
and tubes were centrifuged for 15 minutes at 375xg at room temperature. Supernatant was 
removed and discarded and pellet re-suspended in 1ml Sep medium prior to adding RBCs. 
 
3.11.4. Evaluating monocyte uptake of RBCs (erythrophagocytosis) 
Pre-stained monocytes and CFSE stained RBCs were added together in various 
monocyte:RBC ratios (1:25, 1:50, 1:100). After monocytes were counted under a light 
microscope and RBC count was obtained from FBC data, cell numbers were adjusted in 
order to obtain the different ratios of monocyte to RBCs. One set of tubes comprising of 
monocytes with un-stimulated RBCs and the second set contained the stimulated (H2O2 
treated) RBCs. Tubes were incubated for 1 hour at 37°C at 5% CO2 concentration. After 
incubation period the non-phagocytosed RBCs were lysed by adding 1ml 1X FACS lysing 
solution (BD Biosciences, San Jose, CA, USA) and left at room temperature for 10 minutes. 
Tubes were centrifuged for 15 minutes at 375xg at room temperature and supernatant was 
discarded and the pellet was again re-suspended with 1ml FACS lysing solution and left at 
room temperature for 10 minutes. Tubes were centrifuged for a second time for 15 minutes 
at 375xg at room temperature and supernatant was discarded. Pellet was re-suspended with 
300µl staining buffer and tubes were vortexed. Tubes were stored in a dark place to ensure 
no antibody denaturation occurred until acquisition on the flow cytometer. 
 
3.12. Flow Cytometry 
Data was acquired and analysed on a Becton Dickinson FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA). The CellQuest™ software (BD Biosciences, San Jose, 
CA, USA) was used during acquisition/analysis stages of the study. Fluorescence Minus One 
(FMO) analysis was performed at the initiation phase of flow cytometric analysis in order to 
ensure correct placement of quadrant stats and precise delineation of the positive versus 
negative marker expression. 
 
3.12.1 Analysis of RBC apoptosis in presence/absence of anti-oxidant (NAC) 
Un-stimulated and H2O2 stimulated RBCs treated with or without NAC were assessed. For 
data acquisition on RBCs, using FSC height versus SSC height, 100 000 gated events were 
collected. RBCs express CD235a (glycophorin a) and the gating strategy was designed 
around the expression of this key marker. Using FSC height versus SSC height, the RBC 
population could be amplified and clearly observed and were gated (G1=R1) as illustrated 
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figure 3.2 A. Cells positively expressing the CD235a (RBC marker) in a SSC versus CD235a 
dot plot were then also gated (G2=R2). Other key markers CD41a (platelet specific) and 
CD45 (white blood cell specific) were assessed in order to ensure leukocytes plus platelets 
were excluded. The dot plots that followed illustrating the percentage annexin V expression 
was expressed as a combination of G1+G2 (i.e. G3=R1+R2). Measurement of erythroptosis 
(RBC specific death) is illustrated in Figure 3.2.D.  
3.12.2. Monocyte purity and subset distribution 
A dot plot (CD14 vs. CD16) was constructed to determine monocyte subset distribution. Ten 
thousand FSC height versus SSC height gated events were gathered during purified 
monocyte data acquisition. The monocyte subsets on a forward versus side scatter dot plot 
and were gated (G1=R1). The key markers, CD14 and CD45 were the main focus point for 
the gating strategy on monocytes. Cells were gated on the CD3 negative CD45 positive 
events (G2=R2) in a CD3 versus CD45 dot plot.  Using G2=R2, the cells fluorescing dual 
positivity for CD14 versus CD45 were gated (G3=R3). Using G2=R2 the cells fluorescing 
dual positively for CD14 and CD16 in a CD16 versus CD14 dot plot was gated (G4=R4) 
illustrated in Figure 3.4. G3+G4 were then used in a histogram to measure CD14 expression 
and so were used to obtain our percentage purified monocyte population illustrated in figure 
3.5. 
 
3.12.3. Monocyte up-take of RBCs (erythrophagocytosis) 
Ten thousand FSC height versus SSC height gated events were gathered during functional 
(i.e. phagocytosis) monocyte acquisition. The monocyte subsets in a FSC height versus SSC 
height dot plot was gated on (G1=R1). The key markers, CD14 and CD16 (monocyte 
markers) were the main focus point for the gating strategy on monocytes. CFSE stained 
RBCs (see section 3.11.3.) were evaluated within the CD14 positive CD16 negative or dual 
CD14 and CD16 positive monocyte population. Cells fluorescing positively for both CD14 
and CD16 or positively for only CD14 and negatively for CD16 were gated (G2=R2) on. The 
dot plots that followed illustrating the percentage monocytes expression as a combination of 
G1+G2 (G3=R1+R2).  
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Figure 3.2. RBC gating and measurement of RBC damage. Illustrates the unstained gated RBCs in 
order to determine the double negative populations. These double negative populations indicated 
where quadrants were set. (A) Represents the gating of the non-purified erythrocytes in the FSC 
versus SSC; (B) illustrated that little to no platelets and white blood cells (WBCs) are present in the 
gated RBC population (C) Illustrates example of baseline annexin V expression and (D) example of 
annexin V expression on stimulated RBCs 
 
 
Figure 3.3. Gating strategy and measuring of CD38 expression on CD8+ CTL. Dot plot A illustrates the 
gating of the lymphocyte population based on forward vs. side scatter. Dot plots B and C illustrate the 
CD3+ sub-population, when no gate (B) or the lymphocyte gate (C) was defined. The dot plot (D) 
illustrates the number of CD8+ CTL expressing the CD38+ inflammatory marker (upper right hand 
quadrant) of the CD3 gated events. 
A 
B 
C 
D E 
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Figure 3.4. Purified monocyte gating and subtype identification. Dot plot A represents the purified 
monocyte population, showing gating region based on forward versus side scatter. Dot plots B 
Illustrates the gating on the CD45+CD14+ population to ensure only wanted cells are included Dot plot 
C illustrates the different monocyte populations we focused on namely the classical CD14+CD16- 
population located in the bottom right hand corner and the activated CD14+CD16+ population located 
at the top right hand corner.  
 
Figure 3.5. Monocyte % (M1) obtained before and after purification. Histogram (A) illustrates the CD14 
monocyte population obtained from whole blood (B) the CD14 positive monocyte population after 
purification in order to determine the monocyte purity (see figure 4.19.). 
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4. Resuls 
4.1. Patient Demographic 
A total of 77 individuals were recruited from the HIV counselling, testing and prevention 
(HCTP) clinic (Emavundleni), situated in Crossroads, Cape Town (CT) which forms part of 
the Desmond Tutu HIV Foundation. These 77 individuals included 33 HIV negative (control 
group) and 44 HIV positive individuals. Most of the data generated in this study were non-
parametric and are presented showing median values plus/minus standard deviation (SD). 
The median age in years in the control group was 26±9.3 (range 20-58) compared to a 
median age of 29.5±9.4 (range 23-56) in the positive group. Basic indicators of HIV-1 
infection (CD4 count, viral load, immune activation) as well as other parameters important for 
the current study (RBC count, Hb, Hct, monocyte count and monocyte %) were determined 
using fresh blood samples and methodologies outlined in the Materials and Methods section 
above. Correlations between these basic parameters were performed and are presented. 
These data are presented in Table 4.1 
 
The majority of the data are illustrated graphically using box-and-whisker plots generated 
following statistical analyses using the GraphPad Prism 5 software (GraphPad Software, CA, 
USA). The “box” in the graphs represents the interquartile range (25-75 percentile confidence 
limits). The line present in the box indicates the median and the “whiskers” located at the top 
and bottom of the box represents the 10-90 percentile confidence limits. Data falling outside 
the 10-90 percentile range (outliers) are indicated as dots. A p value of ≤0.05 was indicative 
of statistical significance and is illustrated on the graphs with a bar. Correlations of various 
parameters were also performed within groups with a p value ≤0.05 indicating statistical 
significance and r value =>0 indicating a positive relationship and an r value =<0 indicating a 
negative relationship. 
 
Table 4.1. Patient demographic (data is shown as median values ±SD) 
 Control HIV p-value 
Number of samples 33 44 N/A 
Age (years) 26±9.3 29.5±9.4 N/A 
Age range 20-58 23-56 N/A 
Number of Males 11 8 N/A 
Number of Females 22 36 N/A 
CD4 (cells/µl)  929±288.3 410±234.6 <0.0001 
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CD4 range 470-1691 19-980 N/A 
RBC count  (x106 cells/µl)  4.7±0.5 4.2±0.7 0.0009 
RBC count (x106 cells/µl) range 3.7-5.9 2.8-6.9 N/A 
Hb (g/dl)  14.1±1.9 12.9±1.8 0.0172 
Hb range 7.7-18 8.4-17.5 N/A 
Haematocrit (l/l)  0.43±0.1 0.39±0.1 0.0071 
Haematocrit (l/l) range 0.27-0.55 0.26-0.55 N/A 
Monocytes (x103 cells/µl)  0.32±0.2 0.27±0.1 0.0350 
Monocytes (x103 cells/µl) range 0.18-0.57 0.15-0.44 N/A 
Monocytes %  4.9±2.7 5.9±1.6 0.0246 
Monocytes % range 3.2-8.6 3.2-9.9 N/A 
Viral load (copies/ml) log  N/A 4.1±1.4 N/A 
Viral load (copies/ml) log range N/A 0.0-6.2 N/A 
Activation marker CD38/8 T cell %  10.7±10.3 27.0±17.7 <0.0001 
Activation marker CD38/8 T cell % range 2.3-25.4 5.5-48.8 N/A 
Control = HIV-1 non-infected patients; HIV positive = HIV-1 infected patients 
 
4.2. Basic indicators for HIV-1 infection measured ex vivo 
4.2.1. CD4 counts 
The control group had a median CD4 count more than double the HIV positive group. The 
control group had a median of 929±288.3 cells/µl when compared 410±234.8 cells/µl in the 
HIV positive group, p<0.0001 see Figure 4.1.  
 
Figure 4.1. Box-and-whisker plot illustrating CD4 count data between the 2 groups. The box-and-
whisker plot illustrates the CD4 counts in the two study groups. There was a statistically significant 
difference between the two groups:  HIV-1 median 410±234.6 vs. HIV-1 uninfected median 929±288.3, 
p=<0.0001. 
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4.2.2. Red Blood Cell (RBC) Count 
RBC Counts were obtained by full blood count (FBC). The control group had a higher median 
RCC of 4.7x106±0.5 cells/µl when compared to the median RCC of the HIV positive group of 
4.2x106±0.7 cells/µl (p=0.0009) see figure 4.2. The decreased RBC count is indicative of 
anaemia in the HIV-1 infected group and is confirmed by the haemoglobin data presented 
below. 
 
Figure 4.2. Box-and-whisker plot illustrating RBC count between the 2 groups. These data were 
obtained from routine full blood counts (FBCs). There is a statistically significant difference between 
the RCC of the two groups with the HIV + group showing a 0.5x10
6
 cells/µl statistical decrease when 
compared to the control group with a p=0.0009. 
 
4.2.2.1. Correlations of RBC count with basic indicators of HIV 
No statistically significant correlations were detected between the RCC and CD4 count or 
viral load tests as shown in Table 4.2. This would appear to indicate that neither the CD4 T 
cell subset changes nor the plasma viral load were directly implicated in the RBC decrease. 
This may be due to limited sample size and the selection of a study cohort in which HIV-1 
infection was asymptomatic. Although there appears to be a positive relationship between 
CD4 count and RCC, and a negative relationship between VL and RCC the absence of 
statistical significance, implies that the two important clinical indicators of HIV-1 diseases 
progression were not causally linked to RBC count. Correlations with immune activation 
CD38/8 are discussed below. 
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Table 4.2. Correlation values of RCC with CD4 count and viral load. 
RBC count Control HIV-1 infected 
 r-value p-value r-value p-value 
CD4 count -0.0651 0.7188 0.1168 0.4848 
Viral load (log) N/A N/A -0.003 0.9851 
 
4.2.3 Haemoglobin levels 
Haemoglobin levels were obtained by routine FBC of fresh blood samples. The control group 
had a median Hb level of 14.1±1.9 g/dl compared to 12.9±1.8 g/dl in the HIV-1 positive 
group, p=0.0172 see figure 4.3. The significantly decreased Hb levels are consistent with 
anaemia and the decreased RBC count. 
 
Figure 4.3. Haemoglobin levels between the 2 groups. The box-and-whisker plots illustrate the 
haemoglobin (Hb) levels as measured by FBCs between the two groups. There was  a statistically 
significant difference between the Hb level of the two groups with the HIV + group (12.9±1.8 g/dl) 
showing a statistical decrease when compared to the control group (14.1±1.9 g/dl) with a p=0.0172. 
 
4.2.3.1 Correlations of Hb with basic indicators of HIV 
As with the RBC count data, no statistically significant correlations were detected between 
the Hb and CD4 count or viral load tests as shown in Table 4.3.  
 
Table 4.3. Correlation of Hb with CD4 count and viral load 
Hb Control HIV-1 infection 
 r-value p-value HIV r-value p-value 
CD4 count 0.1277 0.4788 0.1447 0.3862 
Viral load (log) N/A N/A -0.0599 0.7098 
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4.2.4. Haematocrit levels 
Haematocrit (or packed cell volume) levels were obtained by routine FBC. The control group 
had a median of almost double that of the HIV positive group. The control group had a 
median of 0.43 (43%)±0.05 l/l  compared to 0.27 (27%)±0.08 l/l in the HIV positive group, 
p=0.0071 , illustrated in Figure 4.4. 
 
Figure 4.4. Haematocrit levels between the 2 groups. The box-and-whisker plot illustrates the 
haematocrit obtained from FBCs between the two groups. There was a statistically significant 
difference between the haematocrit level of the two groups with the HIV + group (0.27 (27%)±0.08 l/l) 
showing a statistical decrease when compared to the control group (0.43 (43%)±0.05 l/l),  p=0.0071. 
 
Hct data showed a similar trend to both RBC and Hb data, and again a significant difference 
between the two groups. All the red cell parameters show profound targeting and significant 
changes to the red cell compartment, even though our study cohort was “healthy” individuals 
with relatively high CD4 counts. 
 
4.2.4.1. Correlations of Hct with basic indicators of HIV 
No statistically significant correlations were detected between the Hct and CD4 count or viral 
load tests as shown in Table 4.4. The absence of statistical significance was most likely due 
to sample size, especially since the HIV-1 infected group was selected for their “healthy” 
status and relatively high CD4 count. 
 
Table 4.4. Correlations of Hct with CD4 count and viral load 
Hct Control HIV-1 infection 
 r-value p-value r-value p-value 
CD4 count 0.0683 0.7058 0.1044 0.5385 
Viral load (log) N/A N/A -0.0224 0.8893 
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4.2.5. Annexin V baseline 
A novel component of this study was an assessment of RBC apoptosis (erythroptosis) by 
measuring surface expression of PS molecules as detected by annexin V binding. Annexin V 
was measured at baseline (ex vivo) before any stimulation in order to determine the levels of 
damage to the RBCs sustained in vivo. The control group had a lower median % annexin V 
positive RBC value at baseline 10.4±5% when compared to the HIV-1 positive group of 
13.4±4.7%, p=0.0189 see figure 4.5.  
 
Figure 4.5. Annexin V baseline expression on damaged RBCs ex vivo. The box-and-whisker plot 
illustrates the annexin V baseline data measured ex vivo between the two groups. There was  a 
statistically significant difference between the annexin V baseline of the two groups with the HIV-1 
positive group showing a statistical increase when compared to the control group with a p=0.0189. 
 
The significantly increased baseline annexin V (28.8% higher in the HIV-1 infected group) 
was indicative of higher levels of erythrocyte death by erythroptosis.  
 
4.2.5.1. Correlations of annexin V with basic indicators of HIV 
Correlations were performed between annexin V baseline and various other study 
parameters, illustrated in Table 4.5. A significant negative correlation between annexin V 
baseline and RBC count was observed in the control group. This confirmed that the 
decreased RBC count was biologically associated with RBC apoptosis as measured by 
annexin V binding. No statistical correlation was observed in the HIV positive group, 
however. This finding is in accordance with the lack of correlation of the RBC paramaters 
with standard clinical HIV-1 indicators. 
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Figure 4.6. Annexin V baseline versus RBC count correlation. The scatterplot illustrates a negative 
correlation between annexin V baseline expression and RBC in the control group. There was a 
statistically significant difference with a p=0.0401 and r=-0.3592 
 
Table 4.5. Correlations of annexin V baseline with basic HIV; red blood cell and immune 
activation parameters. 
Annexin V baseline  Control HIV-1 infection 
 r-value p-value r-value p-value 
CD4 count -0.0702 0.4229 0.1443 0.6753 
RCC count N/A N/A 0.1219 0.4305 
Hb level -0.2322 0.1934 0.1785 0.2462 
Hct level -0.1583 0.3790 0.2215 0.1535 
Viral load N/A N/A 0.0189 0.9067 
CD38/8 0.2330 0.1920 0.0447 0.7720 
 
4.2.6. Absolute Monocyte Counts 
Absolute monocyte counts were obtained from routine FBC and differential count. Absolute 
monocyte counts were lower in the HIV-1 infected group. The control group had a median 
monocyte count of 0.32x103±0.1 cells/µl when compared to the HIV-1 positive group 
0.27x103±0.08 cells/µl. The decrease was statistically significant, p=0.035. See figure 4.7. 
Even though there was a statistically significant decrease, this was not clinical significant as 
it is still within the normal range of 0.1-0.8 cells/µl. The decrease in monocytes may be due to 
pooling in the tissues at sites of inflammation and infection at this stage of the disease. The 
decrease may also be indicative of increased monocyte apoptosis or decreased production 
from the bone marrow, or a combination of all of these (Gama et al., 2012).  
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Figure 4.7. Monocyte counts obtained from FBC differentials. The box-and-whisker plot illustrates the 
monocyte counts between the two groups. There was a statistically significant difference between the 
two groups with the HIV + (0.27x10
3
±0.08 cells/µl) group showing a statistically lower number of 
monocytes when compared to the control group (0.32x10
3
±0.1 cells/µl), p=0.035. 
 
The relationship of total monocyte count to HIV-1 clinical indicators and to red cell 
parameters was determined statistically. No significant correlations were obtained, indicating 
that changes to the monocyte compartment occurred relatively independently to changes in 
both standard clinical parameters and red cell parameters. 
Table 4.6. Correlation of monocyte count with basic HIV indicators; RBC parameters and 
immune activation levels. No statistically significant correlations were detected with the 
monocyte count. 
Monocyte count  Control HIV-1 infection 
 r-value p-value r-value p-value 
CD4 count 0.0202 0.9111 0.1579 0.3576 
RCC count -0.3265 0.0637 0.1301 0.4177 
Hb level -0.0129 0.4406 -0.1390 0.9361 
Hct level -0.1689 0.3473 0.0804 0.6172 
CD38 -0.0607 0.7372 -0.1438 0.3698 
HIV-1 viral load N/A N/A -0.1091 0.5084 
 
4.2.7. Blood monocyte percentage 
Blood monocyte percentages as a percentage of total leukocytes, were obtained by routine 
FBC and automated differential count on the Siemens Advia 2012. The control group had a 
median monocyte % of 4.9±2.7% when compared to the HIV-1 positive group 6±1.6%. See 
Figure 4.6. Even though there was a statistical significant decrease, there was not a clinically 
significant change, as the normal range is 2-10%. The higher monocyte percentage in the 
HIV-1 positive group may be due to a relative increase in proportion to the total leukocyte 
count as a result of the decreased CD4 counts, which also constitute a fraction of the total 
leukocytes. Please see results of absolute monocyte counts above.  
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Figure 4.8. Monocytes as a percentage of total leukocytes obtained from FBC and differential counts. 
The box-and-whisker plot illustrates the monocyte % (of total leukocytes) data between the two 
groups. There was a statistically significant difference between the two groups with the HIV-1 + group 
showing a statistically higher monocyte % (6±1.6%) when compared to the control group (4.9±2.7%) 
with a p=0.0246. 
 
4.2.7.1. Correlations of monocyte % with basic indicators of HIV and other red blood 
cell parameters 
The monocytes were correlated with the basic clinical indicators of HIV-1 infection (CD4 and 
viral load) as well as RCC, Hb, Haematocrit, and annexin V baseline) in order to determine 
significant relationships. 
 
4.2.7.2.. Relationship of Monocyte % with RCC 
Correlations were performed between monocyte % and red cell counts. There was a 
significant negative correlation in the control group indicating that as the monocyte 
percentage increased the RCC decreased. There was no statistical correlation in the HIV 
positive group.  
 
Figure 4.9. Monocyte % versus RBC count correlation. The scatterplot illustrates a negative 
correlation between the monocyte % and RBC in the control group. There was a statistically significant 
difference with a p=0.0198 and r=-0.4037 
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4.2.7.3. Relationship of monocyte % with Hb 
Correlations were performed between monocyte % and Hb level. There was a significant 
negative correlation in the control group indicating that as the monocyte percentage 
increased the Hb level decreased. There was no statistical correlation in the HIV positive 
group. This finding confirms the relationship between monocyte % and RBC count discussed 
above. 
The negative relationship between monocyte % and RBC parameters was not apparent in 
the HIV-1 infected group, confirming that altered percentages of monocytes (due to changes 
in CD4 counts) disrupted the relationship which was observed in the uninfected donors. 
Figure 4.10. Monocyte % versus Hb level correlation. The scatterplot illustrates a negative correlation 
between the monocyte % and Hg level in the control group. There was a statistical significant 
difference with a p=0.0475 and r=-0.3476 
 
The other parameters did not show statistically significant correlations with monocyte 
percentages, as indicated in Table 4.7. These findings should be considered in the light of 
the relationships of standard parameters to total monocytes, as discussed below. 
Table 4.7. Correlations of monocyte % with basic HIV indicators 
Monocyte %  Control HIV-1 infection 
 r-value p-value r-value p-value 
CD4 count -0.3227 0.0670 -0.0227 0.8953 
RCC count - - -0.1830 0.2521 
Hb - - -0.2877 0.0682 
Hct -0.3414 0.0519 -0.2487 0.1169 
Annexin V baseline 0.2164 0.2264 -0.2482 0.1176 
HIV-1 viral load N/A N/A 0.8010 0.6280- 
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4.2.8. Expression of the activation marker CD38 on CD8+ T cells 
HIV-1 infection leads to the activation of various cells including CD8+ T cells. CD38 is a well-
defined activation marker, particularly well-researched in the context of HIV-1 infection and 
serving as a marker for general immune activation status (Vollbrecht et al., 2010). The HIV 
positive group had almost 3 times the % of CD8 T cells expressing CD38 as did the control 
group. The control group had a median % CD8 T cells expressing CD38 of 10.7±10.3 % vs. 
28.8±17.3 % in the HIV-1 positive group, p<0.0001. See figure 4.11. 
 
Figure 4.11. Immune activation measured by the expression of the activation marker CD38 on CD8+ T 
cells. The box-and-whisker plot illustrates the CD8 activation marker CD38 data between the two 
groups. There is a statistically significant difference between the two groups with the HIV + group 
showing a statistical increase when compared to the control group with a p<0.0001. 
 
The dramatic increase in percentage activated CD8+ T cells is in accordance with published 
literature. The relationship of immune activation (as determined by CD38 expression) to 
other parameters was assessed by statistical correlation. 
 
4.2.8.1. Relationship of % CD38+ CD8+ T cells with basic clinical indicators of HIV-1 
disease; red cell parameters and monocyte count 
The % CD38 expressing CD8+ T cells was correlated with the basic indicators of HIV (CD4, 
viral load), red cell parameters (RCC, Hb, Haematocrit, annexin V baseline), plus monocyte 
percentage and monocyte count in order to determine significant relationships. 
 
4.2.8.2. % CD38 expressing CD8+ T cells and CD4 count 
There was a negative correlation between CD4 cell count and CD38 on CD8 T cells in both 
study groups indicating that as the activation of CD8+ T cells increased the CD4 count 
decreased. However, this correlation was not statistically significant in the control group, but 
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reached statistical significance in the HIV positive group (p=0.0169). This indicates a 
relationship between activated CD8+ T cells and CD4 T cells, as previously published by 
others (Steel et al., 2008). 
 
Figure 4.12. CD4 count versus CD38/8 correlation. The scatterplot illustrates a negative correlation 
between the absolute CD4 count and CD8 activation marker CD38 in the HIV+ group. p=0.0169 and 
r=-0.3853 
 
4.2.8.2. CD38 on CD8 correlating with viral load 
Correlations were performed between CD38/CD8 T cells and viral load in the HIV-1 infected 
group. There was a significant positive correlation indicating that as the viral load increased, 
activation of CD8+ T cells increased. See figure 4.13. The significant relationship between 
CD4 count, viral load and CD38 expression, shows the inter-relatedness of these parameters 
and the importance of these markers, even in a study cohort of “healthy” HIV-1 infected 
individuals. 
 
Figure 4.13. VL versus CD38/8 correlation. The scatterplot illustrates the correlation between the viral 
load (log) and the activation marker CD38 on CD8 T lymphocytes in the HIV+ group. This was 
statistically significant with a p=0.0053 and r=0.4226 
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CD38 did not correlate with other parameters (see Table 4.8). This appears to indicate the 
changes in red cell parameters and monocytes were not directly related to immune 
activation. This may be due to the sample size and the selection of a “healthy” HIV-1 infected 
cohort with fairly high CD4 count. Interestingly, despite the lack of a significant association, a 
negative relationship in the HIV-1 negative group between immune activation and Hb, Hct, 
monocyte count was noted, indicating that higher immune activation may impact on these 
parameters. 
 
Table 4.8. Correlations of CD38 on CD8 T cells with other parameters 
CD38 on CD8  Control HIV-1 infection 
 r-value p-value r-value p-value 
CD4 count -0.1606 0.3720 - - 
RCC -0.0544 0.5094 0.1190 0.7259 
Hb -0.0216 0.9048 -0.1493 0.3333 
Hct 0.0312 0.8634 -0.2487 0.1169 
Monocyte count 0.0813 0.6529 -0.1639 0.3058 
Monocyte % 0.1578 0.3806 0.1981 0.2145 
Annexin V baseline 0.2390 0.1804 0.2482 0.1176 
 
4.3. RBC oxidative stress and efficacy of the antioxidant NAC 
4.3.1. RBC induced oxidative damage (erythroptosis) measured by annexin V 
expression 
Our findings indicated that there was a significant decrease in RBCs, Hb and Hct in HIV-1 
infected individuals (see sections 4.2.2.-4.2.4.), therefore, we wanted to investigate the role 
of oxidative stress on these changes. In order to evaluate this we stimulated cells in vitro with 
an oxidative stressor (H2O2) and then measured the % expression of annexin V. The relative 
amount of oxidative damage was determined by the increase in annexin V expression as 
illustrated in figure 4.14. 
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Figure 4.14. Expression and measurement of % annexin V. The histograms illustrate the percentage 
annexin V expression on gated RBCs as detected by flow cytometry. . (A) Presents unstained and un-
stimulated RBCs, showing the placement of the markers M1 and M2 indicating the separation of 
populations negative and positive for annexin V, respectively.  (B) Presents stained but un-stimulated 
RBCs i.e. baseline annexin V expression (14.4±6.9 %). (C) Presents stained and H2O2 stimulated 
RBCs and the increased annexin V expression (19±6.8 %). 
 
The damage RBCs sustain after induction of oxidative stress in vitro with 5mM H2O2 for an 
hour was measured by annexin V expression. The technique used was previously optimized 
in 2010 in our laboratory. In section 4.2.5.the damage RBCs sustained in vivo was measured 
and illustrated as annexin V baseline. The control group had a median annexin V baseline of 
10.4±5% when compared to the HIV-1 positive group of 13.4±4.7%, p=0.0189 indicating that 
RBC damage was already occurring in vivo. The oxidative stress was then induced on RBCs 
with 5mM H2O2 for 1 hour and the annexin V levels measured. The control group had an 
induced median annexin V % of 15.4±7.4% when compared to the HIV-1 positive group of 
18.5±6.8%, p=0.0232, see Figure 4.15. Both groups had an approximate 5% increase in 
annexin V expression after induced oxidative stress see Figure 4.17. This similar level of 
induced damage in vitro led us to deduce that the RBCs from HIV-1 positive individuals are 
not more sensitive to oxidative stress when compared to the RBCs from the control group 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
50 
 
 
Figure 4.15.Induction of oxidative stress in vitro on RBCs and annexin V measurement. The box-and-
whisker plot illustrates the annexin V expression following induced oxidative stress stimulation on 
homologous RBCs between the two groups. The data illustrated here indicates the damage RBCs 
sustained after in vitro induced oxidative damage while the baseline annexin V indicates the damage 
the RBCs sustain while in vivo illustrated in figure 4.5. There is a statistically significant difference 
between the annexin V expression of the two groups with the HIV + group showing a statistical 
increase when compared to the control group with a p=0.0232. 
 
4.3.2. Comparison of induced oxidative stress using an oxidative buffer (DPBS + 5mM 
sodium-L-ascorbate (Sigma-Aldrich) + 0.4 mM copper (II) sulphates) vs.  H2O2 
The % annexin V expression between the control group (n=13) and HIV-1 (n=14) infected 
group were compared when RBCs were stressed with two oxidative stressors in order to 
determine which stressor would deliver optimal results. It has been reported in the literature 
that H2O2 is unstable and therefore other oxidative stressors in a buffered format may 
produce more consistent results. The control group had a median annexin V % of 15.7±9.2% 
after stimulation with H2O2 when compared to the HIV-1 positive group of 18.9±7.3%, 
p=0.0079. There was a significant difference in the control group when H2O2 stimulated 
samples compared to the un-stimulated samples. Oxidative buffer stimulated samples in the 
control group were 12.1±8.3% compared to the H2O2 stimulated samples 15.7±9.2%, 
p=0.0082. There was a significant difference in the HIV-1 infected group when H2O2 
stimulated samples were compared to the un-stimulated samples as well as the oxidative 
buffer stimulated samples (see Figure 4.16 and Table 4.9.).  
There was no significant difference within the groups between the un-stimulated and 
oxidative buffer stimulated samples. There were, however, significant differences between 
the control group and the HIV-1 infected group at each time point when samples were either 
un-stimulated or oxidative buffer stimulated (see Figure 4.16 and Table 4.9.).  
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Figure 4.16. Induction of oxidative stress with 2 oxidative stressors over time. This was performed to 
compare whether the oxidative buffer would present better results compared to the unstable H2O2. 
The graph illustrates the median % annexin V expression on RBCs between the two groups with 
control group on the left in graph A and the HIV-1 infected group on the right in graph B. The groups 
were either un-stimulated and sampled at three time points (indicated as blue solid circles), stimulated 
with a 5mM H2O2 for 1 hour (represented as black solid triangle) or stimulated with an oxidative buffer 
(DPBS + 5mM sodium-L-ascorbate (Sigma-Aldrich) + 0.4 mM copper (II) sulphates)(indicated as solid 
squires) at three different time stages (represented as red solid squares). There was no statistically 
significant difference between the un-stimulated and oxidative buffer stimulated samples within the two 
groups. There was a statistical significant difference between the H2O2 and the un-stimulated and 
oxidative buffer stimulated samples at the 60 minutes time point in both groups. There was also 
significant differences between the un-stimulated as well as oxidative buffer stimulated samples at 
each time point between the control group and the HIV-1 infected group. Standard deviation and p 
values are indicated above and median values with SD are also presented in table 4.9. below. The SD 
was not indicated on the graph for clarity purposes. The highest level of annexin V expression data 
were obtained from the 5mM H2O2 concentration and the 30 minute time point with the oxidative 
buffer. 
 
The SD and median values relating to figure 4.16. are illustrated in table 4.9 below. The 30 
minute stimulation with the oxidative buffer presented the highest annexin V expression in 
both groups. It may be that annexin decreases over time as annexin positive cells enter late 
apoptosis and degrade, so not being included in the RBC gate. The samples were only 
stimulated for an hour with H2O2 as this presented optimal annexin V expression when 
technique was optimised in 2010 in our laboratory. The median and standard deviation 
annexin V baseline and stimulation of both groups are illustrated in Table 4.9.  
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Table 4.9. Representation of % annexin V expression at each stage of induced oxidative 
stress of figure 4.16 
Form of stimulation and time  Control HIV+ 
H2O2 60 minutes  15.7±9.2 18.9±7.3 
Unstimulated 30 minutes  12.2±7.8 17±10.8 
Oxidative buffer 30 minutes  13.2±9.2 16.6±10 
Unstimulated 60 minutes  11.5±7.9 15.7±9.9 
Oxidative buffer 60 minutes  12.1±8.3 16.1±10.1 
Unstimulated 120 minutes  10.7±7.6 15.9±11.1 
Oxidative buffer 120 minutes  12.4±8.8 16.2±10.8 
 
4.3.3. Induction of oxidative stress using H2O2 
Due to no apparent difference in use of H2O2 vs. the oxidative buffer, further experiments 
were performed using H2O2 alone. At baseline level indicated in section 4.2.5. there was a 
statistically higher annexin V expression in the HIV-1 infected individuals 13.4±4.7% when 
compared to the healthy non-infected group 10.4±5% with a p-value of 0.0189. After 
stimulation with H2O2 the annexin V expression increased in both groups indicated above 
(4.2.9.). The HIV-1 infected individuals expressed a statistically higher annexin V level 
18.5±6.8 when compared to the healthy non-infected group 15.4±7.4% with a p value of 
0.0232. There was also a statistical difference between the baseline level and induced 
oxidative stressed level within each group. The HIV-1 infected individuals had a p value of 
p<0.0001, and the healthy non-infected individuals also had a p<0.0001. The median and 
standard deviation annexin V baseline and stimulation levels of both groups are illustrated in 
Table 4.10. 
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Figure 4.17. Comparison of oxidative damage on RBCs between the two groups at baseline and after 
inducing oxidative stress with 5mM H2O2 for 1 hour. The graph illustrates the median % annexin V 
expression data either un-stimulated/ stimulated with H2O2 between the control group (n=33) and HIV 
group (n=44) There are statistically significant difference between the annexin V baseline and 
stimulated annexin V expression in the two groups with the HIV + group showing a statistically higher 
level to the control group at both points of measurement (un-stimulated and stimulated). There were 
statistical significant differences between baseline levels as well as between induced oxidative stress 
levels of annexin V expression between the two groups as well as within each group. The significant 
difference at baseline annexin V expression between the two groups p=0.0189, is illustrated as ¤. The 
significant difference after induced oxidative stress between the two groups, p=0.0232 is illustrated as 
#. The significant difference between baseline level and after induced oxidative stress within the 
control group, p<0.0001 is illustrated as ~. The significant difference between baseline level and after 
induced oxidative stress within the HIV-1 group, p<0.0001 is illustrated as *. 
 
Table 4.10. Representation of % annexin V expression when un-stimulated or stimulated 
Form of stimulation  Control HIV+ 
Un-stimulated Baseline median 10.4±5 13.4±4.7 
Stimulated H2O2 median 15.4±7.4 18.5±6.8 
 
In summary, the data presented in figure 4.17 indicates that although HIV-1 infected 
individuals have a higher baseline annexin V expression, the RBCs in both study groups 
responded in a similar manner to H2O2 induced oxidative stress. In both groups a significant 
increase in annexin V positivity was observed, but the increase was equivalent in both 
groups. This appears to confirm that the RBCs in HIV infection were not more sensitive in 
vitro to oxidative stress. Alternatively, oxidative stress in vitro may induce higher levels of 
RBC apoptosis which causes cell degradation, with degraded cells being excluded from RBC 
analysis. The finding that longer oxidative stress incubation times reduced annexin V binding 
(Fig 4.16) may be evidence for this, In which case a shift into late apoptosis was being 
detected as decreased early apoptosis. The damage to RBCs caused in vivo in HIV-1 
infection does however translate into elevated overall RBC death following in vitro application 
of oxidative stress. 
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4.3.4. The effects of the anti-oxidant NAC on RBCs measured 
The counter measure that the anti-oxidant (NAC) has on the oxidative stress induced in 
RBCs by H2O2 was measured by changes in annexin V expression. The anti-oxidant had an 
impact on the RBCs, buffering them almost completely from the harmful effects of the 
oxidative stressor. During this part of the study 20 control samples and 30 HIV-1 infected 
samples were processed. The impact of increasing concentrations of NAC on annexin V 
expression is illustrated in Figure 4.18. 
 
Figure 4.18. Dose response of NAC before and after inducing oxidative stress with H2O2. The graph 
illustrates the median % annexin V data between the control (n=20) group and HIV+ (n=30) group un-
stimulated/ stimulated with a 5mM H2O2 for an hour in association with or without the anti-oxidant n-
acetyl cysteine (NAC) at various concentrations (2.5mM, 5mM and 10mM). There was no significant 
difference between the control group and the HIV-1 positive group. The optimal inhibition by NAC 
occurred at the 10mM concentration for both study groups. 
 
Table 4.11. Representation of median % annexin V expression at each stage of NAC dose 
Stimulation  Control HIV+ 
 Un-stimulated H2O2 Un-stimulated H2O2 
No NAC  13.6±4.1 20±5.1) 12.8 ±5.2 18.3 ±5.0 
2.5mM NAC  14.2±3.4 14.9 ±4.1 13.1 ±4.6 16.8 ±5.1 
5mM NAC 15.4 ±3.3 17.2 ±4.4 13.1 ±4.9 16 ±5.5 
10mM NAC 14.3 ±3.4 15 ±4.4 13 ±5.2 16 ±5.2 
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Although NAC inhibited induced oxidative stress in both groups, the uninfected group 
displayed stronger inhibition. At 10mM NAC, the oxidative stress induced apoptotic 
percentage of RBCs was reduced from 20±5.1% to 15±4.4% (p=0.0063). In other words, the 
6.4% increase due to oxidative stress was reduced to 1.4%. In the HIV-1 group, the oxidative 
stress induced apoptotic percentage of RBCs was reduced from 18.3±5.0% to 16±5.2%. 
(p=0.0649). In this case, the 5.5% increase due to oxidative stress was reduced to 3.2%. 
NAC thus appears less efficient in minimizing induced oxidative stress in vitro in the HIV-
infected group. 
 
4.4. Monocyte:RBC interaction 
Having established that RBCs are depleted in chronic HIV and that this depletion is 
accompanied by increased annexin V expression, we next wanted to investigate the 
relationship of RBC depletion to monocyte cell numbers and function (particularly 
phagocytosis). Monocytes were purified as discussed in section 3.9. The purity of monocytes 
was assessed with the use of flow cytometry (see Figure 4.19).  
 
Purity of separated monocytes 
Figure 4.19. Flow cytometric histogram plot showing purity of monocytes before and after enrichment 
from whole blood. The graph represents a histogram measuring the CD14 expression in whole blood 
before purification (in purple) and after purification (green line) in order to obtain the percentage 
purified monocyte population. M1 measures the CD14-CD45+ population and M2 the CD14+CD45+. 
The percentage CD14+CD45+ monocytes (M2) obtained from whole blood was ±5.7% from total 
gated events before purification. The percentage monocytes (M2) obtained after purification was 
>70% of total gated events. 
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4.4.1. Comparison of the relative proportion of classical (CD14+CD16-) and 
inflammatory (CD14+CD16+) monocyte subsets between the study groups 
The control group had a slightly (but statistically insignificant) higher percentage of classical 
monocytes when compared to the HIV-1 infected group. The control group had a median 
CD14+/16- monocyte % of 65.6±7.1 when compared to the HIV positive group of 63.4±8.8.  
 
Figure 4.20. Comparison of the classical (CD14+/16-) monocyte subset between the two groups. The 
box-and-whisker plot illustrates the % classical (CD14+/16-) monocytes as % of total gated monocyte 
events between the two groups. Although median decreased in HIV-1 there was no statistically 
significant difference between the two groups with a p=0.1597. 
 
The changes in classical monocyte percentages mirror the total monocyte count changes 
(Figure 4.10). Although both total monocyte count and inflammatory subset % differences 
(see below) were significant, this was not the case for the classical subset, as the data was 
fairly widely spread. 
Figure 4.21. CD4 count versus classical monocyte correlation. The scatterplot illustrates the 
correlation between the CD4 count and the classical monocyte (CD14+CD16-) population in the 
control group. This was statistically significant with a p=0.0135 and r=0.5424 
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There was a significant correlation between the classical monocyte (CD14+CD16-) 
population and CD4 count in the control group, p=0.0135 and r=0.5424 illustrated in figure 
4.21 above. There were no significant differences between the classical monocyte and any 
HIV-1 parameters or RBC parameters (see Table 4.12.) other than that described above. 
 
Table 4.12. Correlations between the classical (CD14+CD16-) monocyte population and 
HIV-1 paramaters or RBC parameters 
Classical monocyte 
(CD14+CD16-) 
Control HIV-1 infected 
 p-value r-value p-value r-value 
CD4 count Significant Significant 0.9900 -0.0024 
RCC 0.1545 -0.3306 0.7439 0.0622 
Hb 0.1129 -0.3657 0.7640 0.0572 
Hct 0.0780 -0.4031 0.6587 0.0841 
Annexin V baseline 0.3253 0.2318 0.8543 -0.0350 
Annexin V 0.4528 -0.1780 0.7458 0.0618 
CD38/8 0.4181 0.1917 0.4840 -0.1329 
VL N/A N/A 0.3561 -0.1812 
 
There was a significant increase in the % inflammatory monocytes in the HIV-1 infected 
group. The control group had a median inflammatory monocyte % of 5.3±3.8 when compared 
to the HIV-1 positive group of 8.3±3.5, p=0.0054.  
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Figure 4.22. Comparison of the inflammatory (CD14+/16+) monocyte subset between the two groups. 
The box-and-whisker plot illustrates the inflammatory (CD14+/16+) monocyte between the two groups. 
There is a statistically significant difference between the inflammatory monocyte populations of the two 
groups with the HIV + group showing a statistical increase when compared to the control group with a 
p=0.0054. 
 
The significant increase in the inflammatory subset of monocytes in HIV-1 infection may be 
due to the overall increase in immune activation (as evidenced by CD38 data). Although 
absolute monocyte counts were reduced in HIV-1, the % inflammatory cells were significantly 
increased. This would imply an overall increase in inflammatory monocytes. If 5.3% of 
monocytes were inflammatory in the uninfected group this would equate to 0.53x0.32x103 
cells/µl (0.1696x103 cell/µl) vs. 8.3% or 0.83x0.27x103 (0.2241x103 cells/µl), representing 
almost double the number in the HIV-1 infected group. 
 
Figure 4.23. CD38+ CTL versus inflammatory monocyte correlation. The scatterplot illustrates the 
correlation between the CD38+ CTL and the inflammatory monocyte (CD14+CD16+) population in the 
control group. This was statistically significant with a p=0.0363 and r=0.4705 
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There was a significant correlation between the inflammatory monocyte (CD14+CD16+) 
population and CD38/8 expression in the control group, p=0.0363 and r=0.4705 illustrated in 
figure 4.23 above. There were no significant correlations between the classical monocyte 
and any HIV-1 parameters or RBC parameters (see Table 4.13.) other than that described 
above. 
 
Table 4.13. Correlations between the classical (CD14+CD16-) monocyte population and 
HIV-1 parameters or RBC parameters 
Inflammatory 
monocyte 
(CD14+CD16+) 
Control HIV-1 infected 
 p-value r-value p-value r-value 
CD4 count 0.1478 -0.3358 0.9712 0.0069 
RCC 0.2409 -0.2748 0.9511 -0.0117 
Hb 0.4671 -0.1725 0.9800 -0.0048 
Hct 0.7344 -0.0810 0.9900 -0.0024 
Annexin V baseline 0.9147 0.0256 0.8121 -0.0453 
Annexin V 0.4423 -.01821 0.5244 -0.1209 
CD38/8 Significant Significant 0.2759 0.2055 
VL N/A N/A 0.4553 0.1470 
 
4.4.2. RBC phagocytotic potential of monocyte subsets at various monocyte to RBC 
ratios 
The link between the monocyte and red cell compartments would most likely be at the level 
of apoptosis. Monocytes are the major cell involved in clearance of RBCs from the circulation 
– primarily in the spleen. Having established increased levels of apoptotic RBCs in HIV-1 
infection, we investigated the interaction between monocytes and RBCs and how monocyte 
subsets differed in their ability to phagocytose these cells. 
 
In order to test the ability of autologous monocytes to phagocytose RBCs, purified 
monocytes were exposed to RBCs at different monocyte:RBC ratios (as described in section 
3.11.4.). Phagocytosis was measured by flow cytometry. RBCs were stained with CFSE prior 
to phagocytosis and the % of monocytes staining positive for CFSE was assessed at the end 
of the experiments. Figure 4.24 illustrates typical flow data generated. 
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Figure 4.24. Phagocytosis of RBCs by monocytes at various monocyte:RBC ratios. (A) Representative 
histogram illustrating pure monocytes in purple containing no RBCs and showing placement of M2 
CFSE erythrocyte marker. Graphs B-D represents the % f monocytes staining positive for CFSE, 
illustrated as a green line. Histogram B presents the number of monocytes taking up dead/dying RBCs 
when at a ratio of 1 monocyte to 25 stimulated RBCs (a total of 6.8% monocytes were CFSE positive). 
Histogram C represents a 1:50 ratio (total of 48.5% monocytes were CFSE positive) and histogram D 
a 1:100 ratio (total of 95.7% monocytes were CFSE positive). 
 
4.4.3. 1 Monocyte to various RBC ratio’s (25; 50 and 100) 
In the phagocytosis experiments, the data was summarized as the median % of monocytes 
phagocytozing RBCs. The total monocyte fraction and the classical and inflammatory 
subsets were evaluated separately. Figure 4.25 shows the difference in phagocytotic 
potential of total monocytes. There was no significant difference in total monocyte phagocytic 
potential at all 3 ratios examined. Figure 4.26 illustrates that the same trend was observed 
when examining the classical (CD14+CD16-) monocyte subset. Figure 4.27 shows the 
phagocytic potential of the inflammatory (CD14+CD16+) monocyte subset, again showing no 
significant difference between the two study groups (i.e. HIV-1 negative versus HIV-1 
positive). 
These data illustrate that monocyte function is not impaired in HIV-1 infection, with 
comparable phagocytosis occurring at the designated monocyte:RBC ratios. 
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Figure 4.25. Phagocytosis of H2O2 stressed RBCs at different ratio’s by monocytes. Graph A (box-
and-whisker plot) illustrates a 1 monocyte to 25 stimulated RBC ratio between the two groups. Graph 
B illustrates a 1 monocyte to 50 stimulated RBC ratio between the two groups. Graph C illustrates a 1 
monocyte to 100 stimulated RBC ratio between the two groups. There were no significant difference in 
the total number of monocytes between the control group (n=20) and the HIV-1 infected group (n=30) 
at any of the monocyte:RBC  ratios. 
 
The control group had a higher phagocytosis rate when compared to the total monocyte 
population of the HIV positive group at 1:25 ratio. There was no statistically significant 
difference between the two groups with a p=0.8897. At 1 monocyte to 50 stimulated RBC 
ratio between the two groups, the control group had a lower phagocytosis rate when 
compared to the HIV positive group. There was no statistically significant difference between 
the two groups with a p=0.5459. At 1 monocyte to 100 stimulated RBC ratio between the two 
groups, the control group had a lower phagocytosis rate when compared to the HIV positive 
group. There was no statistically significant difference between the two groups with a 
p=0.7478 (see Figure 4.25. and Table 4.14). 
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Figure 4.26. Phagocytosis of oxidative induced RBCs by the classical monocyte (CD14+/16-) subset. 
Graph A (box-and-whisker plot) illustrates a 1 classical monocyte (CD14+/16-) to 25 stimulated RBC 
ratio between the two groups. Graph B illustrates a 1 monocyte to 50 stimulated RBC ratio between 
the two groups. Graph C illustrates a 1 monocyte to 100 stimulated RBC ratio between the two 
groups. There were no significant difference between the control group (n=20) and the HIV-1 infected 
group (n=30) at any of the monocyte:RBC ratios. 
 
The control group had a lower phagocytosis rate when compared to the classical monocyte 
population (CD14+/16-) of the HIV positive group at 1:25 ratio. There was no statistically 
significant difference between the two groups with a p=0.4458. At 1 classical monocyte to 50 
stimulated RBC ratio between the two groups, the HIV-1 infected group had a lower 
phagocytosis rate when compared to the control group. There was no statistically significant 
difference between the two groups with a p=0.9290. At 1 classical monocyte to 100 
stimulated RBC ratio between the two groups, the control group had a higher phagocytosis 
rate when compared to the HIV positive group. There was no statistical significant difference 
between the two groups with a p=0.5458 (see Figure 4.26. and Table 4.14). 
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Figure 4.27. Phagocytosis of oxidative induced RBCs by the inflammatory monocyte (CD14+/16+) 
subset. Graph A (box-and-whisker plot) illustrates a 1 activated monocyte (CD14+/16+) to 25 
stimulated RBC ratio between the two groups. Graph B illustrates a 1 monocyte to 50 stimulated RBC 
ratio between the two groups. Graph C illustrates a 1 monocyte to 100 stimulated RBC ratio between 
the two groups. There were no significant difference between the control group (n=20) and the HIV-1 
infected group (n=30) at any of the monocyte:RBC ratios. 
 
The control group had a lower phagocytosis rate when compared to the inflammatory 
(CD14+/16+) monocyte population of the HIV positive group at 1:25 ratio. There was no 
statistically significant difference between the two groups with a p=0.6136. At 1 activated 
monocyte to 50 stimulated RBC ratio between the two groups, the HIV-1 infected group had 
a lower phagocytosis rate when compared to the control group. There was no statistically 
significant difference between the two groups with a p=0.9921. At 1 activated monocyte to 
100 stimulated RBC ratio between the two groups, the control group had a higher 
phagocytosis rate when compared to the HIV positive group. There was no statistically 
significant difference between the two groups with a p=0.8276 (see Figure 4.27 and Table 
4.14). 
Although there was no apparent difference in the phagocytotic potential of total monocytes or 
the subsets between the two groups, there was an enhanced capacity for phagocytosis by 
inflammatory monocytes in both study groups. 
At the 25:1 ratio the inflammatory subset showed significantly enhanced phagocytosis as 
compared to the classical subset, in both the control and infected study groups. This would 
Stellenbosch University  http://scholar.sun.ac.za
64 
 
appear to implicate the expanded, more phagocytic inflammatory subset in the clearance of 
the expanded apoptotic RBC population. 
 
Table 4.14. Representation of median % CFSE expression and SD at each RBC:monocyte 
ratio 
RBC:monocyte 
ratio 
Classical Inflammatory 
 Control HIV-1 infected Control HIV-1 infected 
25:1 13.8±12.9 17.2±15.6 22±14.3 27.9±18.1 
50:1 24.8±29 27.9±32 68.1±27.5 56.3±26.9 
100:1 96.4±21.1 92.3±18.3 96.4±11.2 94.8±11.6 
 
4.4.4. Impact of RBCs oxidative stress on RBC up-take by the inflammatory 
(CD14+CD16+) monocyte subset at various monocyte to un-stimulated versus 
stimulated RBC ratios in the HIV+ group 
Having established that the inflammatory subset is expanded in chronic HIV-1 infection and 
that the inflammatory subset is significantly more phagocytic of RBCs, we wished to 
investigate the impact of RBC apoptosis as induced by oxidative stress on the relative 
phagocytic potential of inflammatory monocytes. In section 4.3 we showed that H2O2 
stressing led to approximately 18.5% of RBC becoming apoptotic. The increased red cell 
apoptosis induced by oxidative stress translated into increased phagocytosis at 25:1 ratio 
(5.2% vs. 2.9%), however this was not statistically significant. These data indicate that the in 
vitro oxidative stressing of the cells did not significantly impact on the phagocytic uptake. 
Increases in apoptotic RBCs of 3-4% were mirrored by a similar increase in phagocytosis (at 
25:1 ratio) of 2.3%. There would appear to be a link between level of RBC apoptosis and 
phagocytosis, but due to moderate difference in apoptotic RBCs between the study groups, 
this did not lead to significant phagocytosis increase. 
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Figure 4.28. Determining the up-take capabilities of un-stimulated/stimulated RBCs by the 
inflammatory (CD14+CD16+) monocyte subset in the HIV-1 group. Graph A (box-and-whisker plot) 
illustrates a 1 activated monocyte (CD14+/16+) to 25 stimulated RBC ratio within the HIV-1 infected 
group. Graph B illustrates a 1 monocyte to 50 stimulated RBC ratio within the HIV-1 infected group. 
Graph C illustrates a 1 monocyte to 100 stimulated RBC ratio within the HIV-1 infected group. There 
were no significant differences between the uptake of un-stimulated RBCs (n=13) and the stimulated 
RBCs (n=13) by autologous monocytes at any of the RBC:monocyte ratios. 
 
At a ratio of 1 activated monocyte (CD14+/16+) to 25 un-stimulated/stimulated RBC within 
the HIV positive group, the stimulated RBCs were phagocytosed twice as much by the 
inflammatory monocyte population as when RBCs were not stimulated with H2O2. There was 
no statistically significant difference between the two groups but there was a trend towards 
statistical significant with a p=0.0803. At 1 activated monocyte to 50 un-stimulated/stimulated 
RBC ratio within the HIV positive group, the un-stimulated RBCs were phagocytosed less by 
the inflammatory monocyte population as when RBCs were stimulated with H2O2. There was 
no statistically significant difference between the two groups with a p=0.2500. At 1 activated 
monocyte to 100 unstimulated/stimulated RBC ratio within the HIV positive group, the 
stimulated RBCs were phagocytosed more by the inflammatory monocyte population as 
when RBCs were not stimulated with H2O2. There was no statistically significant difference 
between the two groups but there was a trend towards statistical significance with a 
p=0.5000. 
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4.4.5. Phagocytosis of oxidatively stressed induced RBCs by the different monocyte 
subsets (classical (CD14+CD16-) and inflammatory (CD14+CD16+)) at various 
monocyte to RBC ratios 
Having established that oxidative stress in vitro did not significantly alter phagocytosis by 
inflammatory monocytes between the 2 study groups, we next investigated how the two 
monocyte subsets differed in phagocytic ability within the study groups. 
4.4.5.1. Classical/ Inflammatory monocytes at 25:1 RBC:monocyte  ratios 
The inflammatory monocyte subset phagocytosed almost twice as many erythroptotic RBCs 
when compared to the classical monocyte subset of the control group. The inflammatory 
subset had a median of 22±14.3% compared to 13.8±12.9 in the classical subset. p=0.0002. 
See figure 4.29 
Figure 4.29. Comparison of the up-take capabilities between the different monocyte subsets in the 
control group at a 1 monocyte to 25 RBC ratio. The box-and- whisker plot illustrates classical 
(CD14+/16-) monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 25 stimulated RBC 
ratio within the control groups. There was a statistically significant difference between the two 
monocyte subsets with more activated monocytes engulfing damaged RBCs with a p=0.0002. 
 
The classical subset phagocytosed 30% less erythroptotic RBCs when compared to the 
inflammatory monocyte subset in the HIV-1 infected group at a RBC:monocyte ratio of 25:1. 
The classical monocyte subset had a median of 17.2±15.6% phagocytic cells and the 
inflammatory monocyte subset a median of 27.9±18.1%, p<0.0001. See figure 4.30. 
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Figure 4.30. Comparison of the up-take capabilities between the different monocyte subsets in the HIV 
group at a 1 monocyte to 25 RBC ratio. The box-and-whisker plot illustrates classical (CD14+/16-) 
monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 25 stimulated RBC ratio within the 
HIV positive groups. There was a statistical significant difference between the two monocyte subsets 
with more activated monocytes engulfing damaged RBCs with a p<0.0001. 
 
4.4.5.2. Classical/Inflammatory 50:1 RBC:monocyte ratio 
The inflammatory monocyte subset phagocytosed more than 10% more erythroptotic RBCs 
when compared to the classical monocyte subset in the control group. The inflammatory 
subset had a median of 72.9±26.5% compared to 65.5±28.4%, p=0.0015 in the classical 
subset see figure 4.31. 
 
Figure 4.31. Comparison of the up-take capabilities between the different monocyte subsets in the 
control group at a 1 monocyte to 50 RBC ratio. The box-and-whisker plot illustrates classical 
(CD14+/16-) monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 50 stimulated RBC 
ratio within the control groups. There was a statistical significant difference between the two monocyte 
subsets with more activated monocytes engulfing damaged RBCs with a p=0.0015. 
 
The inflammatory monocyte subset phagocytosed significantly less erythroptotic RBCs when 
compared to the classical monocyte subset in the HIV-1 infected group at this ratio. The 
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inflammatory monocyte subset had a median of 58.9±25.7% and the classical monocyte 
subset a median of 60.9±28.1%, p<0.0001. See figure 4.32. 
 
Figure 4.32. Comparison of the up-take capabilities between the different monocyte subsets in the HIV 
group at a 1 monocyte to 50 RBC ratio. The box-and-whisker plot illustrates classical (CD14+/16-) 
monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 50 stimulated RBC ratio within the 
HIV-1 positive groups. There was a statistical significant difference between the two monocyte subsets 
with more classical monocytes engulfing damaged RBCs with a p=0.0015. 
 
4.4.5.3. 1 Classical/Inflammatory monocyte to 100 RBC ratio 
The inflammatory monocyte subset phagocytosed a greater number of erythroptotic RBCs 
when compared to the classical monocyte subset in the control group. The inflammatory 
subset had a median of 95.6±26.5% compared to 96.4±28.4% in the classical subset, 
p=0.0465. See figure 4.33. 
Figure 4.33. Comparison of the up-take capabilities between the different monocyte subsets in the 
control group at a 1 monocyte to 100 RBC ratio.The box-and-whisker plot illustrates classical 
(CD14+/16-) monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 100 stimulated RBC 
ratio within the control groups. There was a statistically significant difference between the two 
monocyte subsets with more activated monocytes engulfing damaged RBCs with a P=0.0465. 
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The inflammatory monocyte subset phagocytosed more erythroptotic RBCs when compared 
to the classical monocyte subset in the HIV-1 infected group. The inflammatory monocyte 
subset had a median of 94.8±11.6% and the classical monocyte subset a median of 
94.6±16.4%, p=0.0066. See figure 4.34. 
Figure 4.34. Comparison of the up-take capabilities between the different monocyte subsets in the HIV 
group at a 1 monocyte to 100 RBC ratio. The box-and-whisker plot illustrates classical (CD14+/16-) 
monocytes versus the  activated monocytes (CD14+/16+) at a 1 to 100 stimulated RBC ratio within the 
HIV positive groups. There was a statistical significant difference between the two monocyte subsets 
with more activated monocytes engulfing damaged RBCs with a p=0.0066. 
 
These data show that the inflammatory subset of monocytes was significantly more 
phagocytic than the classical subset. The expanded inflammatory monocyte subset in HIV-1 
may be linked to the increased apoptotic red cell uptake of the expanded erythroptotic 
population. 
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Chapter 5. Discussion 
Summary of data: 
In the current study, we examined anaemia in chronic asymptomatic HIV-1 infection, with a 
particular focus on erythrocyte apoptosis, oxidative stress and immune activation, and the 
impact of changes in the erythrocyte compartment on monocyte-mediated phagocytosis. A 
summary of the major findings is outlined below, followed by a detailed discussion of the 
findings in relation to the published literature. 
 
We have shown evidence for anaemia in chronic HIV-1 infection when compared to healthy 
HIV-1 uninfected individuals with significantly decreased RCC, Hb and Hct levels. The HIV-1 
infected group had a median Hb of (12.9±1.8 g/dl) which was below the cut off level for 
anaemia (see section 2.7) and significantly lower than the control group (14.1±1.9 g/dl), 
p=0.0172. No significant correlates of red cell parameters with CD4 count, VL, or CD38/8 
were detected – however trends  were observed suggesting red cell changes may be related 
to HIV disease (e.g. RCC relationship to CD4 (+ve), VL (-ve) and CD38/8 (-ve). The HIV-1 
infected group had a significantly higher baseline RBC annexin V expression when 
compared to the control group (13.4±4.7% vs. 10.4±5%, p=0.0189). This indicates that RBC 
damage occurs in vivo. Oxidative stress-induced upregulation of annexin V in vitro led to a 
5% (control group) and 5.1% (HIV-1 infected group) increase in RBC-associated annexin V, 
indicating that the RBCs from HIV-1 positive individuals are not more sensitive to 
administered oxidative stress when compared to the RBCs from the control group.  
Although NAC inhibited induced oxidative stress in both groups, the uninfected group 
displayed better inhibition. At 10mM NAC, the oxidative stress-induced annexin V expression 
was significantly reduced (from 20±5.1% to 15±4.4% (p=0.0063)). In other words, the 6.4% 
expression increase induced by oxidative stress was reduced to only 1.4% above baseline. 
In the HIV-1 group, the oxidative stress-induced annexin V expression was reduced from 
18.3±5.0% to 16±5.2%. (p=0.0649). In this case, the 5.5% increase due to oxidative stress 
was reduced to 3.2%. NAC thus appears less efficient in minimizing induced oxidative stress 
in vitro in the HIV-infected group. 
 
Absolute monocyte count was reduced in chronic HIV-1, with the control group having a 
median absolute monocyte count of 0.32x103±0.1 cells/µl when compared to the HIV-1 
positive group 0.27x103±0.08 cells/µl (p=0.035). Although the control group had a higher 
CD14+/16- classical monocyte % of 65.6±7.1 when compared to the HIV positive group of 
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63.4±8.8 there was no statistical significance, p=0.1597. There was, however, a significant 
increase in the inflammatory (CD14+/16+) monocyte subset in the HIV-1 infected population 
when compared to the control population. The inflammatory subset in the control group 
constituted 5.3±3.8% when compared to the HIV-1 positive group of 8.3±3.5%, p=0.0054. 
The monocytes were equally phagocytic in the 2 study groups; however the inflammatory 
subset was significantly more phagocytic than the classical subset in both groups. 
We have thus shown that anaemia is a feature of chronic HIV-1, even when patients are 
asymptomatic and CD4 count is relatively well maintained. This anaemia is multi-factorial 
and not due solely to the virus, CD4 T cell lymphopenia or generalised immune activation. 
Importantly, this study demonstrated significantly increased annexin V expression on 
erythrocytes, an indicator of erythroptosis. Increased oxidative stress is a feature of 
inflammation, and we were able to show that oxidative stress could increase baseline levels 
of annexin V expression. The antioxidant NAC was able to abrogate the induced oxidative 
stress damage in vitro, but elevated baseline erythroptosis in HIV-1 infection would appear to 
indicate that erythrocytes were “primed” to die in vivo.  
Erythrocytes function primarily in homeostasis via haemoglobin-associated transport. 
Importantly, erythrocyte removal is mediated by monocytes and macrophages primarily 
located in the spleen but also in circulation. In this study we confirmed that monocytes were 
decreased in peripheral blood in chronic HIV-1 infection, however the inflammatory subset 
was significantly expanded. We also showed that the inflammatory subset of monocytes was 
the major phagocytic population and that phagocytosis of erythrocytes was affected by their 
annexin V expression.  
 
5.1. Hypothesis 
The original hypothesis of this study was that anaemia in chronic HIV-1 is linked to increased 
RBC death (erythroptosis), most likely due to oxidative stress, and that increased 
erythroptosis would be evident in the enhanced uptake (phagocytosis) of RBCs by 
monocytes.  
We were able to partially verify the hypothesis: namely that RBC death was elevated in 
anaemic HIV-1 positive individuals. We also showed increased phagocytosis of erythroptotic 
RBCs by the expanded inflammatory monocyte subset. We could only partially verify a link 
between oxidative stress and erythroptosis, but did show partial inhibition of oxidative stress-
induced apoptosis by NAC.  
This is the first study to our knowledge to examine both erythrocyte death and associated 
monocyte uptake of erythrocytes in the context of chronic HIV-1 infection. Treating anaemic 
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HIV-1 patients with antioxidants (or reducing inflammation) would reduce erythrocyte death 
and remove the pressure on the monocyte population. There may also be downstream 
effects on monocytes, such as activation following phagocytosis, which could amplify the 
inflammation via secretion of cytokines. A very important finding is that changes in the 
monocyte population may be linked to enhanced erythrocyte death.  
 
5.2. Basic indicators of HIV-1 
It is well established that CD4 T cell numbers are decreased in chronic HIV-1 infection (Ford 
et al., 2009; Aubert et al., 2011; Ofotokun et al., 2012). We found a statistically significant 
lower CD4 T lymphocyte count in the HIV-1 positive group compared to the control group. 
Not only are CD4 T lymphocytes directly infected by the virus, but indirect mechanisms such 
as ‘bystander’ apoptosis, also promote the loss of these cells (Badley et al., 2000). CD4 T 
lymphocytes are therefore a valuable basic indicator of disease status in HIV infection.  
Several studies have shown changes in the erythrocyte compartment in chronic HIV-1 
infection. The changes may be related to anaemia of chronic disease or to unique HIV-1 
infection associated features – such as virally induced changes, immune 
activation/inflammation changes and changes in other blood cell compartments. In the 
current study there was a statistically significant decrease in the RCC in the HIV-1 positive 
group when compared to the control group, p=0.0009. In a study by Abdollahi et al. (2010) 
conducted in Iran, RCC levels in 100 HIV-1 negative and 90 HIV-1 positive patients were 
assessed. The investigators showed a significantly lower RCC in the HIV-1 positive 
individuals as compared to the control group, p<0.001. The lower RCC could be due to a 
number of contributing factors; however, chronic immune activation with ROS production 
appears to have been the major exacerbating cause. Although the RCC levels in their study 
were slightly lower than the levels found in our study, we obtained a statistically lower RCC 
within the HIV-1 infected group compared to the control group, p=0.0009. 
In a study by Obirikorang et al. (2009) a statistically lower Hb level in HIV-1 positive mothers 
was found when compared to the control group of HIV-1 negative mothers, p≤0.0001. Their 
study was conducted in the Cape Coast in Ghana. In our study we also found statistically 
lower haemoglobin levels in the HIV-1 positive group when compared to the control group, 
p=0.0172. Since Hb forms part of RBCs, the decrease of Hb should be linked to the 
decrease in RBCs.  
In our study, a significantly lower Hct level was found in the HIV-1 positive group compared 
to the control group. Omoregie et al. (2008) obtained similar results with p=0.001. Both the 
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haemoglobin and haematocrit levels are linked to the decreasing RCC levels in HIV-1 
positive patients.  
Anaemia is thus a well-described problem in HIV-1 infected individuals with decreased red 
cell parameters (RCC, Hb and Hct). The study group which we examined were not yet on 
ART; they were asymptomatic and had relatively well maintained CD4 counts. 
Total monocyte count in chronic HIV-1 is not as well described as % monocyte subset 
distribution (see section 5.5. below). In a small study by Cobb et al. (2011) the total 
monocyte population in 8 healthy HIV-1 negative and 8 HIV-1 infected patients was 
measured. They found a small decrease in the HIV-1 infected group compared to the Control 
group, which was not significant p=0.079 (Cobb et al., 2011). The results we obtained in our 
study indicated a lower monocyte count in the HIV-1 infected group when compared to the 
control group, p=0.035. Although there was a statistical lower monocyte count in the HIV-1 
group compared to the control group there was no clinical significance as the monocyte 
count still fell within the normal range. The difference in the results obtained between the two 
studies could be due to the smaller sample size used in their study. The overall monocyte 
count was lower in the HIV-1 infected group when compared to the control group in the 
current study. When the total monocyte count was divided into subsets, there was a lower 
classical monocyte population in the HIV-1 infected group compared to the control group 
(p=0.1597), but a statistical increase in the inflammatory population in the HIV-1 infected 
group when compared to the control group, p=0.0054. It is likely that monocytes are recruited 
to sites of infection/inflammation; therefore absolute counts appear decreased in the 
peripheral blood. 
Numerous studies have researched the activation marker CD38 on CD8+ T cells in chronic 
HIV-1 infection. Steel et al. (2008) found a statistically significant increase in the percentage 
CD38 expression in HIV-1 positive patients compared to healthy controls, p<0.0001. In 
another study, Card et al. (2009) reported similar findings with an increase in CD38 
expression in the HIV-1 positive group when compared to the healthy controls, p<0.001. 
These results agree with our findings and support the concept of activation of CTLs in HIV-1 
positive individuals, p<0.0001. 
Furthermore, increased CD38 expression has been shown to predict for a worse prognosis in 
HIV infection, irrespective of viral load or CD4 counts (Hazenberg et al., 2003). 
 
5.3. Baseline annexin V expression on RBCs 
There are many studies that have examined annexin V baseline expression on RBCs in 
other animals or on other cell types such as lymphocytes in HIV-1 infected individuals, 
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(Muratori et al., 2009)(Gama et al., 2012). However, our study is the first to our knowledge to 
examine these levels on RBCs in the context of HIV-1 infection. Our study is novel not only in 
the determination of these levels in RBCs, but also from the concept of measuring levels of 
expression of annexin V as an indication of in vivo inflammatory damage. In our study we 
measured the baseline expression ex vivo and found a statistically significant increase in the 
HIV-1 positive group when compared to the healthy non-infected controls. There are very few 
reports of impact of disease states on RBC baseline annexin V expression in humans. 
However Felder et al. (2011) determined the annexin V baseline expression on RBCs in 
healthy pigs and pigs infected with hemotrophic mycoplasma (HM). In the healthy controls 
they found almost undetectable levels of annexin V expression, but found much higher levels 
in the infected pigs (Felder et al., 2011). The levels of annexin V baseline expression in the 
healthy pigs were much lower than those found in our study conducted on healthy non-
infected humans. It is important to note that baseline annexin V levels in our study did not 
correlate with viral load; suggesting that factors other than the virus itself (such as the 
translocation of gut microbial products)(Ipp et al., 2013), are likely to contribute to the 
inflammatory-induced oxidative stress sustained by the red blood cells. 
 
5.4. Induction of Oxidative stress on RBCs with or without anti-oxidant NAC 
A number of studies have looked at annexin V expression on various cells in various chronic 
conditions. In a study performed by Vota et al. (2012), the exposure of phosphatidylserine 
before and after incubation with aluminium to induce oxidative damage on RBCs was 
examined. Before stimulation, a low annexin V percentage was obtained and after 
stimulation the annexin V expression increased significantly, p<0.05 (Vota et al., 2012). In 
our study, RBCs were stimulated with H2O2 and not aluminium as in their study. They 
reported much higher levels of annexin V expression than obtained in our study; 
nevertheless we also obtained significantly increased annexin V expression from baseline in 
both the control group (p<0.0001) and HIV-1 infected group (p<0.0001) as well as the 
maximum annexin V expression between the 2 groups after stimulation with H2O2, p=0.0232. 
In our study we found that oxidative stress in vitro increased RBC death, but the increase 
was equivalent in both the control and HIV-1 infected groups. On this basis we concluded 
that RBCs were not more sensitive to oxidative stress in the HIV positive group when 
compared to the control group, but had higher levels of damage already occurring in vivo 
most likely due to a more pro-apoptotic milieu. Healthy controls are likely to have a low 
inflammatory status allowing for compensated oxidative stress levels. Individuals that have 
high inflammatory environments such as HIV-1 positive individuals, produce significant 
amounts of oxidative stressors that are likely to contribute to the damage sustained by RBCs 
and result in increased exposure of phosphatidylserine. 
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Several studies have looked at the use of antioxidants to rescue cells (but not RBCs) from 
oxidative stress in HIV-1 infected individuals (Battin et al., 2009)(Kamboj et al., 2010). In a 
study conducted by Matarrese et al. (2005), oxidative stress was induced in RBCs by 
stimulation with 50 µM peroxynitrite (ONOO-). Peroxynitrite is formed when hydrogen 
peroxide (H2O2) is mixed with nitrite. N-acetyl cysteine naïve samples stimulated with ONOO
- 
expressed high annexin V levels due to the oxidative damage sustained. The samples 
incubated with the anti-oxidant NAC prior to stimulation with ONOO- expressed half the 
annexin V levels than was found when RBCs were incubated with only ONOO-, suggesting 
that NAC dampened the damage caused by oxidative stress (Matarrese et al., 2005). In our 
study we found annexin V expression levels similar to their study. In addition, we were able 
to demonstrate significant reduction in annexin V expression in the control group samples 
incubated with NAC, with levels returning almost to baseline within the control group, but with 
less well dampened levels in the HIV-1 infected group. This may indicate that NAC could 
prevent oxidative stress and thereby limit RBC death. This may also suggest that dampening 
oxidative stress in vivo may be beneficial in limiting the severity of anaemia in HIV infection. 
 
5.5. Monocyte subsets and phagocytosis of erythroptotic RBCs 
Unlike FBC monocyte count data, monocyte subsets have been more thoroughly 
investigated in HIV-1 infection. Han et al. (2009) conducted a study in 2009 on 97 HIV-1 non-
infected and 68 HIV-1 infected individuals all recruited in Beijing, China. They divided the 
total numbers of isolated monocytes into their different subsets and found that there was a 
statistical decrease in the number of CD14+/CD16- (classical) monocyte population in the 
HIV-1 positive group when compared to the healthy control group, p<0.0001. They also 
found a significantly increased  CD14+CD16+ (inflammatory) monocyte population of the 
HIV-1 positive group compared to the control group (Han et al., 2009). Their finding of a 
statistical decrease in classical monocyte population in the HIV-1 positive group was similar 
to our study where we found a slightly lower classical monocyte population in the HIV-1 
positive group when compared to the control group. Another study by Ansari et al. (2012) 
also found a similar trend when comparing the classical and inflammatory monocyte 
populations of HIV-1 infected individuals thus adding support to our findings. They also found 
a slight decrease in the classical monocyte population (p=0.138) and a significant increase in 
the inflammatory monocyte population in the HIV-1+ group when compared to the healthy 
control group, p=0.004 (Ansari et al., 2012). These findings suggest that the CD14+CD16+ 
monocyte subset is expanded in HIV-1 infected individuals and this may be related to 
immune activation. The concurrent increase in inflammatory monocytes and apoptotic RBCs 
may also suggest that changes in the RBC compartment could affect the monocyte 
compartment.  
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Several studies have investigated phagocytosis of RBCs by macrophages but not specifically 
phagocytosis by monocytes in the peripheral blood; thus we have only macrophage data for 
comparison. We looked at monocytes due to their importance in inflammation and also due 
to their interaction with red cells in the bloodstream as well as being precursors of 
macrophages in the spleen. A study by Cambos et al. (2011) analysed the uptake of oxidized 
RBCs by macrophages. They measured RBC uptake by measuring CFSE expression in the 
macrophages the same way as we measured the oxidized RBC uptake in monocytes. In our 
study, we incubated three different ratios of oxidized RBCs to autologous monocytes (1:25, 
1:50 and 1:100) in healthy and HIV-1 infected individuals; whereas in the Cambos study they 
incubated 200 oxidized RBCs to 1 macrophage. In our study, there was low to moderate 
uptake of oxidized RBCs by monocytes at the first two ratios in both the healthy and infected 
groups. The results obtained during our highest ratio (1:100) of RBCs to monocytes 
presented similar results when compared to their data (Cambos et al., 2011).  
This is the first study, to our knowledge, that has measured the phagocytosis of erythroptotic 
RBCs in HIV-1 infected individuals. Other studies have investigated the uptake capacity of 
the different monocyte subsets using various nanoparticles. Mosig et al. ( 2009) investigated 
the phagocytosis of oxidized low-density lipoproteins (LDL) by the classical (CD14+CD16-) 
monocyte population in a healthy control group compared with familial hypercholesterolemia 
(FH) group. They also investigated the phagocytic capacity of the inflammatory 
(CD14+CD16+) monocyte populations in the FH group and healthy controls. It was found 
that there was no difference between the uptakes of the oxidative LDL when comparing the 
classical monocyte population between the two groups. The inflammatory monocyte 
population showed a slight increase in the FH group compared to the healthy individuals but 
this did not reach statistical significance (Mosig et al., 2009). These results, although not in 
the same chronic disease as our study; concurred with our findings indicating that the 
classical and inflammatory monocyte populations may be equally functional in the study 
group with disease as compared to the control group. 
Ours is also the first study to our knowledge that investigated phagocytosis of RBCs by the 
different subsets of monocytes in HIV-1 infection. A study by Aguilar-Ruiz et al. (2011) 
researched the uptake efficacy of the classical monocyte population compared to the 
inflammatory monocyte population from healthy (HIV-1 negative) donors. Various cells were 
stimulated with zymosan (ligand found on fungi that stimulates a sterile inflammatory 
environment) or LPS and then incubated with either the classical or the inflammatory 
monocyte population. They found a statistically significant increase in the uptake of cells in 
the inflammatory monocyte population when compared to the classical monocyte population 
(Aguilar-Ruiz et al., 2011). These results support our findings of the increased uptake of 
RBCs stimulated with H2O2 by the inflammatory subset. We also observed a significant 
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increase in the uptake in the autologous inflammatory monocyte population when compared 
to the autologous classical monocyte population. These results indicate that cells damaged 
by inflammatory environments such as in HIV-1 infection; are likely to be more readily taken 
up and disposed of by the expanded inflammatory monocyte population than the classical 
monocyte population. 
This is also the first study to our knowledge that has investigated the up-take capabilities of 
un-stimulated versus stimulated apoptotic RBCs by the inflammatory monocyte subset in 
HIV-1 infected individuals. T. Mikołajczyk et al. (2009) researched the uptake capabilities of 
freshly isolated (un-stimulated) or apoptotic (stimulated) polymorphonuclear leukocytes 
(PMN) by the inflammatory (CD14+CD16+) monocyte population of healthy (HIV-1 negative) 
donors. The data obtained in their study indicated that only a low percentage of un-
stimulated PMN cells were ingested by the inflammatory monocyte population. When the 
inflammatory monocytes were incubated with stimulated PMN cells there was a profound 
increase of percentage cells ingested (Mikołajczyk et al., 2009). Their findings concur with 
the results we obtained when inflammatory monocytes of HIV-1 infected individuals were 
incubated with either healthy autologous RBCs or oxidative stressed autologous RBCs: there 
was also a statistically significant increase in the uptake of oxidatively stressed RBCs by the 
inflammatory monocyte population. Our findings suggest that the in vivo damage during 
inflammatory conditions, as seen in HIV infection, may drive a need for the increased 
disposal of dead/dying cells by the expanded activated inflammatory monocytes.  
These results strengthen the idea that the inflammatory environment associated with HIV 
infection is an important factor leading to the development of anaemia. The free radicals (for 
instance H2O2) produced by monocytes (Bae et al., 2009) during HIV-1 infection may not be 
the only oxidative stressor playing a part in the development of anaemia, but may be a major 
role player leading to its development (Johnson et al., 2010). The activation of monocytes 
that remove dead/dying RBCs as a result of oxidative stress; is likely to contribute to the 
development of anaemia not only in HIV-1 infected individuals but also in other chronic 
inflammatory conditions. 
 
5.6. Limitations of study 
Our study had several limitations. The study had a cross-sectional design; so individuals 
could not be followed up to determine the prognostic value of these findings. The section 
(see section 4.4.4. above) focussing on up-take of un-stimulated/stimulated RBCs with H2O2 
by the inflammatory monocyte population only incorporated analysis of the inflammatory 
monocyte population of the HIV-1 positive individuals and not of the controls. The work on 
oxidative stress and antioxidant rescue was performed in vitro. Detailed assessment of these 
Stellenbosch University  http://scholar.sun.ac.za
78 
 
phenomena in vivo would require patient-based studies. Certain trends may also have been 
statistically significant with a larger sample size. 
 
5.7. Summary of findings and future questions 
In summary, RBCs were found to be damaged in vivo in HIV-1 infected individuals 
presenting a higher level of early apoptosis when compared to healthy non-infected 
individuals. Importantly, the HIV-1 infected group were clinically well, not on treatment and 
had relatively well maintained CD4 counts (mean: 400 cells/µl) and yet they were already 
showing signs of in vivo inflammatory-induced stress to their RBCs. The anti-oxidant NAC 
was found to dampen the damage caused to RBCs by oxidative stress (but less effectively in 
HIV-1 positive individuals). There was no difference in the total number of monocytes, but 
there was a shift in the monocyte subsets in the HIV-1 positive group. An increase in the 
inflammatory monocyte subset was detected and this is most likely a result of on-going 
immune activation in HIV infection. The inflammatory monocyte subset was more effective in 
phagocytosing damaged/dead RBCs than the classical monocyte subset. The inflammatory 
monocytes were also found to be more efficient at phagocytosing oxidative stressed RBCs 
compared to healthy RBCs.  
5.8. Future questions 
Future studies are needed to address the impact of RBC phagocytosis on monocytes and 
whether they become activated or whether they die. How the monocyte findings relate to 
macrophages also needs to be investigated. In addition, measuring oxidative stress and 
antioxidant levels in patients and relating those values to erythroptosis etc. needs to be 
studied. Finally, monitoring patient Hb and Annexin V levels in follow up cohort studies with 
an intervention arm incorporating the use of N-Acetyl cysteine needs to be investigated. 
These issues are being addressed in planned and ongoing studies. 
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Chapter 6. Conclusion 
This was the first study to our knowledge describing increased erythroptosis at baseline level 
and after induced oxidative stress in chronic HIV-1. This is also the first study to link the 
expansion of the phagocytic inflammatory monocyte subset with erythrocyte damage. The 
red cell compartment may represent an underappreciated component in HIV-1 pathogenesis.  
Studies have shown that anaemia is a common occurrence in HIV-1 infected individuals 
(Weiss, 2009)(Libregts et al., 2011). An important contributing factor is persistent immune 
activation and inflammation. In support of this, we were able to demonstrate CTLs 
expressing higher levels of the activation marker (CD38/8) in HIV-1 positive individuals than 
in healthy individuals. The CTL activation marker was three times higher in the HIV-1 positive 
patients compared to the HIV-1 negative individuals which is in agreement with previous 
studies and this has significant implications for prognosis (Steel et al., 2008; Funderburg et 
al., 2012).  
Monocytes are recruited to sites of infection and inflammation (Mikołajczyk et al., 2009). 
Recruited monocytes produce ROS that could cause oxidative stress to surrounding cells 
(Zawada et al., 2011). Damage to erythrocytes was higher in HIV-1 infected individuals 
compared to healthy non-infected individuals at baseline level suggesting that damage of 
cells already occurred in vivo. Erythrocytes stimulated with H2O2 in vitro showed equivalent 
increases in early apoptosis in both groups suggesting that RBCs from HIV-1 infected 
individuals are not more sensitive to oxidative stress than RBCs from healthy non-infected 
individuals. 
The idea that anti-oxidants could be beneficial in chronic diseases was reinforced by our 
results. Anti-oxidants have previously been shown to reduce the level of erythroptosis 
(Matarrese et al., 2005), but this is the first study to our knowledge to demonstrate this in the 
context of HIV infection. Our patients had not yet developed clinical anaemia, but already 
had significantly lower Hb, RCC and Hct levels than the uninfected controls. This suggests 
that enhanced removal of RBCs from the system was already occurring in this asymptomatic 
stage of HIV infection. We therefore propose that anti-oxidant therapy (or treatment with anti-
inflammatory agents) would be beneficial in limiting the development of anaemia in the early 
stages of chronic HIV-1 infection. A longitudinal study will be important to determine the 
impact of anti-oxidant treatment on erythroptosis.  
During chronic HIV-1 infection, as a result of ongoing immune activation, there is a change in 
the monocyte subset distribution resulting in an increase in the number of the inflammatory 
monocytes (Said et al., 2010). This is the first study to our knowledge to demonstrate that the 
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expanded inflammatory monocytes in HIV-1 infection were more effective in phagocytosing 
autologous oxidatively stressed RBCs compared to the classical monocyte population. These 
results suggest that both inflammation and immune activation facilitate the development of 
anaemia not only by inducing more damage to RBC membranes, but also by stimulating the 
clearance of these RBCs through enhanced phagocytosis by activated monocytes. The use 
of anti-oxidants may inhibit the early apoptotic changes on RBCs and thereby limit their 
clearance from the system. In addition, treatment with anti-inflammatory agents may inhibit 
monocyte activation which occurs simultaneously with RBC damage.
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